Search

Your search keyword '"Meng, X"' showing total 19,133 results
Start Over Author "Meng, X"
19,133 results on '"Meng, X"'

1. Interim report for the International Muon Collider Collaboration (IMCC)

Author

Accettura, C., Adrian, S., Agarwal, R., Ahdida, C., Aimé, C., Aksoy, A., Alberghi, G. L., Alden, S., Amapane, N., Amorim, D., Andreetto, P., Anulli, F., Appleby, R., Apresyan, A., Asadi, P., Mahmoud, M. Attia, Auchmann, B., Back, J., Badea, A., Bae, K. J., Bahng, E. J., Balconi, L., Balli, F., Bandiera, L., Barbagallo, C., Barlow, R., Bartoli, C., Bartosik, N., Barzi, E., Batsch, F., Bauce, M., Begel, M., Berg, J. S., Bersani, A., Bertarelli, A., Bertinelli, F., Bertolin, A., Bhat, P., Bianchi, C., Bianco, M., Bishop, W., Black, K., Boattini, F., Bogacz, A., Bonesini, M., Bordini, B., de Sousa, P. Borges, Bottaro, S., Bottura, L., Boyd, S., Breschi, M., Broggi, F., Brunoldi, M., Buffat, X., Buonincontri, L., Burrows, P. N., Burt, G. C., Buttazzo, D., Caiffi, B., Calatroni, S., Calviani, M., Calzaferri, S., Calzolari, D., Cantone, C., Capdevilla, R., Carli, C., Carrelli, C., Casaburo, F., Casarsa, M., Castelli, L., Catanesi, M. G., Cavallucci, L., Cavoto, G., Celiberto, F. G., Celona, L., Cemmi, A., Ceravolo, S., Cerri, A., Cerutti, F., Cesarini, G., Cesarotti, C., Chancé, A., Charitonidis, N., Chiesa, M., Chiggiato, P., Ciccarella, V. L., Puviani, P. Cioli, Colaleo, A., Colao, F., Collamati, F., Costa, M., Craig, N., Curtin, D., D'Angelo, L., Da Molin, G., Damerau, H., Dasu, S., de Blas, J., De Curtis, S., De Gersem, H., Del Moro, T., Delahaye, J. -P., Denisov, D., Denizli, H., Dermisek, R., Valdor, P. Desiré, Desponds, C., Di Luzio, L., Di Meco, E., Di Petrillo, K. F., Di Sarcina, I., Diociaiuti, E., Dorigo, T., Dreimanis, K., Pree, T. du, Edgecock, T., Fabbri, S., Fabbrichesi, M., Farinon, S., Ferrand, G., Somoza, J. A. Ferreira, Fieg, M., Filthaut, F., Fox, P., Franceschini, R., Ximenes, R. Franqueira, Gallinaro, M., Garcia-Sciveres, M., Garcia-Tabares, L., Gargiulo, R., Garion, C., Garzelli, M. V., Gast, M., Gerber, C. E., Giambastiani, L., Gianelle, A., Gianfelice-Wendt, E., Gibson, S., Gilardoni, S., Giove, D. A., Giovinco, V., Giraldin, C., Glioti, A., Gorzawski, A., Greco, M., Grojean, C., Grudiev, A., Gschwendtner, E., Gueli, E., Guilhaudin, N., Han, C., Han, T., Hauptman, J. M., Herndon, M., Hillier, A. D., Hillman, M., Holmes, T. R., Homiller, S., Jana, S., Jindariani, S., Johannesson, S., Johnson, B., Jones, O. R., Jurj, P. -B., Kahn, Y., Kamath, R., Kario, A., Karpov, I., Kelliher, D., Kilian, W., Kitano, R., Kling, F., Kolehmainen, A., Kong, K. C., Kosse, J., Krintiras, G., Krizka, K., Kumar, N., Kvikne, E., Kyle, R., Laface, E., Lane, K., Latina, A., Lechner, A., Lee, J., Lee, L., Lee, S. W., Lefevre, T., Leonardi, E., Lerner, G., Li, P., Li, Q., Li, T., Li, W., Voti, R. Li, Lindroos, M., Lipton, R., Liu, D., Liu, M., Liu, Z., Lombardi, A., Lomte, S., Long, K., Longo, L., Lorenzo, J., Losito, R., Low, I., Lu, X., Lucchesi, D., Luo, T., Lupato, A., Métral, E., Mękała, K., Ma, Y., Mańczak, J. M., Machida, S., Madlener, T., Magaletti, L., Maggi, M., Durand, H. Mainaud, Maltoni, F., Mandurrino, M., Marchand, C., Mariani, F., Marin, S., Mariotto, S., Martin-Haugh, S., Masullo, M. R., Mauro, G. S., Mazzolari, A., Mele, B., Meloni, F., Meng, X., Mentink, M., Miceli, R., Milas, N., Mohammadi, A., Moll, D., Montella, A., Morandin, M., Morrone, M., Mulder, T., Musenich, R., Nardecchia, M., Nardi, F., Neuffer, D., Newbold, D., Novelli, D., Olvegård, M., Onel, Y., Orestano, D., Osborne, J., Otten, S., Torres, Y. M. Oviedo, Paesani, D., Griso, S. Pagan, Pagani, D., Pal, K., Palmer, M., Pampaloni, A., Panci, P., Pani, P., Papaphilippou, Y., Paparella, R., Paradisi, P., Passeri, A., Pastrone, N., Pellecchia, A., Piccinini, F., Piekarz, H., Pieloni, T., Plouin, J., Portone, A., Potamianos, K., Potdevin, J., Prestemon, S., Puig, T., Qiang, J., Quettier, L., Rabemananjara, T. R., Radicioni, E., Radogna, R., Rago, I. C., Ratkus, A., Resseguie, E., Reuter, J., Ribani, P. L., Riccardi, C., Ricciardi, S., Robens, T., Robert, Y., Roger, C., Rojo, J., Romagnoni, M., Ronald, K., Rosser, B., Rossi, C., Rossi, L., Rozanov, L., Ruhdorfer, M., Ruiz, R., Queiroz, F. S., Saini, S., Sala, F., Salierno, C., Salmi, T., Salvini, P., Salvioni, E., Sammut, N., Santini, C., Saputi, A., Sarra, I., Scarantino, G., Schneider-Muntau, H., Schulte, D., Scifo, J., Sen, T., Senatore, C., Senol, A., Sertore, D., Sestini, L., Rêgo, R. C. Silva, Simone, F. M., Skoufaris, K., Sorbello, G., Sorbi, M., Sorti, S., Soubirou, L., Spataro, D., Stamerra, A., Stapnes, S., Stark, G., Statera, M., Stechauner, B. M., Su, S., Su, W., Sun, X., Sytov, A., Tang, J., Taylor, R., Kate, H. Ten, Testoni, P., Thiele, L. S., Garcia, R. Tomas, Mugglestone, M. Topp, Torims, T., Torre, R., Tortora, L. T., Trifinopoulos, S., Udongwo, S. -A., Vai, I., Valente, R. U., van Rienen, U., van Weelderen, R., Vanwelde, M., Velev, G., Venditti, R., Vendrasco, A., Verna, A., Verweij, A., Verwilligen, P., Villamzar, Y., Vittorio, L., Vitulo, P., Vojskovic, I., Wang, D., Wang, L. -T., Wang, X., Wendt, M., Widorski, M., Wozniak, M., Wu, Y., Wulzer, A., Xie, K., Yang, Y., Yap, Y. C., Yonehara, K., Yoo, H. D., You, Z., Zanetti, M., Zaza, A., Zhang, L., Zhu, R., Zlobin, A., Zuliani, D., and Zurita, J. F.

Subjects
Physics - Accelerator Physics, High Energy Physics - Experiment
Abstract

The International Muon Collider Collaboration (IMCC) [1] was established in 2020 following the recommendations of the European Strategy for Particle Physics (ESPP) and the implementation of the European Strategy for Particle Physics-Accelerator R&D Roadmap by the Laboratory Directors Group [2], hereinafter referred to as the the European LDG roadmap. The Muon Collider Study (MuC) covers the accelerator complex, detectors and physics for a future muon collider. In 2023, European Commission support was obtained for a design study of a muon collider (MuCol) [3]. This project started on 1st March 2023, with work-packages aligned with the overall muon collider studies. In preparation of and during the 2021-22 U.S. Snowmass process, the muon collider project parameters, technical studies and physics performance studies were performed and presented in great detail. Recently, the P5 panel [4] in the U.S. recommended a muon collider R&D, proposed to join the IMCC and envisages that the U.S. should prepare to host a muon collider, calling this their "muon shot". In the past, the U.S. Muon Accelerator Programme (MAP) [5] has been instrumental in studies of concepts and technologies for a muon collider., Comment: This document summarises the International Muon Collider Collaboration (IMCC) progress and status of the Muon Collider R&D programme

Published
2024

3. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death

Author

Jia, Jia, Ji, Wenbo, Saliba, Antoine N., Csizmar, Clifford M., Ye, Kaiqin, Hu, Lei, Peterson, Kevin L., Schneider, Paula A., Meng, X. Wei, Venkatachalam, Annapoorna, Patnaik, Mrinal M., Webster, Jonathan A., Smith, B. Douglas, Ghiaur, Gabriel, Wu, Xinyan, Zhong, Jun, Pandey, Akhilesh, Flatten, Karen S., Deng, Qingmei, Wang, Hongzhi, Kaufmann, Scott H., and Dai, Haiming

Published
2024
Full Text
View/download PDF

4. Observation of gamma rays up to 320 TeV from the middle-aged TeV pulsar wind nebula HESS J1849$-$000

Author

Amenomori, M., Asano, S., Bao, Y. W., Bi, X. J., Chen, D., Chen, T. L., Chen, W. Y., Chen, Xu, Chen, Y., Cirennima, Cui, S. W., Danzengluobu, Ding, L. K., Fang, J. H., Fang, K., Feng, C. F., Feng, Zhaoyang, Feng, Z. Y., Gao, Qi, Gomi, A., Gou, Q. B., Guo, Y. Q., Guo, Y. Y., Hayashi, Y., He, H. H., He, Z. T., Hibino, K., Hotta, N., Hu, Haibing, Hu, H. B., Hu, K. Y., Huang, J., Jia, H. Y., Jiang, L., Jiang, P., Jin, H. B., Kasahara, K., Katayose, Y., Kato, C., Kato, S., Kawahara, I., Kawashima, T., Kawata, K., Kozai, M., Kurashige, D., Labaciren, Le, G. M., Li, A. F., Li, H. J., Li, W. J., Li, Y., Lin, Y. H., Liu, B., Liu, C., Liu, J. S., Liu, L. Y., Liu, M. Y., Liu, W., Lu, H., Meng, X. R., Meng, Y., Munakata, K., Nagaya, K., Nakamura, Y., Nakazawa, Y., Nanjo, H., Ning, C. C., Nishizawa, M., Noguchi, R., Ohnishi, M., Okukawa, S., Ozawa, S., Qian, X., Qian, X. L., Qu, X. B., Saito, T., Sakakibara, Y., Sakata, M., Sako, T., Sako, T. K., Sasaki, T., Shao, J., Shibata, M., Shiomi, A., Sugimoto, H., Takano, W., Takita, M., Tan, Y. H., Tateyama, N., Torii, S., Tsuchiya, H., Udo, S., Wang, H., Wang, S. F., Wang, Y. P., Wangdui, Wu, H. R., Wu, Q., Xu, J. L., Xue, L., Yang, Z., Yao, Y. Q., Yin, J., Yokoe, Y., Yu, Y. L., Yuan, A. F., Zhai, L. M., Zhang, H. M., Zhang, J. L., Zhang, X., Zhang, X. Y., Zhang, Y., Zhang, Yi, Zhang, Ying, Zhao, S. P., Zhaxisangzhu, Zhou, X. X., and Zou, Y. H.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

Gamma rays from HESS J1849$-$000, a middle-aged TeV pulsar wind nebula (PWN), are observed by the Tibet air shower array and the muon detector array. The detection significance of gamma rays reaches $4.0\, \sigma$ and $4.4\, \sigma$ levels above 25 TeV and 100 TeV, respectively, in units of Gaussian standard deviation $\sigma$. The energy spectrum measured between $40\, {\rm TeV} < E < 320\, {\rm TeV}$ for the first time is described with a simple power-law function of ${\rm d}N/{\rm d}E = (2.86 \pm 1.44) \times 10^{-16}(E/40\, {\rm TeV})^{-2.24 \pm 0.41}\, {\rm TeV}^{-1}\, {\rm cm}^{-2}\, {\rm s}^{-1}$. The gamma-ray energy spectrum from the sub-TeV ($E < 1\, {\rm TeV}$) to sub-PeV ($100\, {\rm TeV} < E < 1\, {\rm PeV}$) ranges including the results of previous studies can be modeled with the leptonic scenario, inverse Compton scattering by high-energy electrons accelerated by the PWN of PSR J1849$-$0001. On the other hand, the gamma-ray energy spectrum can also be modeled with the hadronic scenario in which gamma rays are generated from the decay of neutral pions produced by collisions between accelerated cosmic-ray protons and the ambient molecular cloud found in the gamma-ray emitting region. The cutoff energy of cosmic-ray protons $E_{\rm p\, cut}$, cut is estimated at ${\rm log}_{10}(E_{\rm p,\, cut}/{\rm TeV}) = 3.73^{+2.98}_{-0.66}$, suggesting that protons are accelerated up to the PeV energy range. Our study thus proposes that HESS J1849$-$000 should be further investigated as a new candidate for a Galactic PeV cosmic-ray accelerator, PeVatron., Comment: 10 pages, 2 figures, Accepted for publication from the Astrophysical Journal

Published
2023
Full Text
View/download PDF

5. Measurement of the Gamma-Ray Energy Spectrum beyond 100 TeV from the HESS J1843$-$033 Region

Author

Amenomori, M., Asano, S., Bao, Y. W., Bi, X. J., Chen, D., Chen, T. L., Chen, W. Y., Chen, Xu, Chen, Y., Cirennima, Cui, S. W., Danzengluobu, Ding, L. K., Fang, J. H., Fang, K., Feng, C. F., Feng, Zhaoyang, Feng, Z. Y., Gao, Qi, Gomi, A., Gou, Q. B., Guo, Y. Q., Guo, Y. Y., He, H. H., He, Z. T., Hibino, K., Hotta, N., Hu, Haibing, Hu, H. B., Hu, K. Y., Huang, J., Jia, H. Y., Jiang, L., Jiang, P., Jin, H. B., Kasahara, K., Katayose, Y., Kato, C., Kato, S., Kawashima, T., Kawata, K., Kozai, M., Kurashige, D., Labaciren, Le, G. M., Li, A. F., Li, H. J., Li, W. J., Li, Y., Lin, Y. H., Liu, B., Liu, C., Liu, J. S., Liu, L. Y., Liu, M. Y., Liu, W., Liu, X. L., Lou, Y. -Q., Lu, H., Meng, X. R., Meng, Y., Munakata, K., Nagaya, K., Nakamura, Y., Nakazawa, Y., Nanjo, H., Ning, C. C., Nishizawa, M., Ohnishi, M., Okukawa, S., Ozawa, S., Qian, L., Qian, X., Qian, X. L., Qu, X. B., Saito, T., Sakakibara, Y., Sakata, M., Sako, T., Sako, T. K., Shao, J., Shibata, M., Shiomi, A., Sugimoto, H., Takano, W., Takita, M., Tan, Y. H., Tateyama, N., Torii, S., Tsuchiya, H., Udo, S., Wang, H., Wang, Y. P., Wangdui, Wu, H. R., Wu, Q., Xu, J. L., Xue, L., Yang, Z., Yao, Y. Q., Yin, J., Yokoe, Y., Yu, N. P., Yuan, A. F., Zhai, L. M., Zhang, C. P., Zhang, H. M., Zhang, J. L., Zhang, X., Zhang, X. Y., Zhang, Y., Zhang, Yi, Zhang, Ying, Zhao, S. P., Zhaxisangzhu, and Zhou, X. X.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

HESS J1843$-$033 is a very-high-energy gamma-ray source whose origin remains unidentified. This work presents, for the first time, the energy spectrum of gamma rays beyond $100\, {\rm TeV}$ from the HESS J1843$-$033 region using the data recorded by the Tibet air shower array and its underground muon detector array. A gamma-ray source with an extension of $0.34^{\circ} \pm 0.12^{\circ}$ is successfully detected above $25\, {\rm TeV}$ at $(\alpha,\, \delta) = (281.09^{\circ}\pm 0.10^{\circ},\, -3.76^{\circ}\pm 0.09^{\circ})$ near HESS J1843$-$033 with a statistical significance of $6.2\, \sigma$, and the source is named TASG J1844$-$038. The position of TASG J1844$-$038 is consistent with those of HESS J1843$-$033, eHWC J1842$-$035, and LHAASO J1843$-$0338. The measured gamma-ray energy spectrum in $25\, {\rm TeV} < E < 130\, {\rm TeV}$ is described with ${\rm d}N/{\rm d}E = (9.70\pm 1.89)\times 10^{-16} (E/40\, {\rm TeV})^{-3.26\pm 0.30}\, {\rm TeV}^{-1} {\rm cm}^{-2} {\rm s}^{-1}$, and the spectral fit to the combined spectra of HESS J1843$-$033, LHAASO J1843$-$0338, and TASG J1844$-$038 implies the existence of a cutoff at $49.5\pm 9.0\, {\rm TeV}$. Associations of TASG J1844-038 with SNR G28.6$-$0.1 and PSR J1844-0346 are also discussed in detail for the first time., Comment: 11 pages, 4 figures, 1 table

Published
2023
Full Text
View/download PDF

7. Silver Nanoparticles Exposure Impairs Cardiac Development by Suppressing the Focal Adhesion Pathway in Zebrafish

Author

Lu C, Wu X, Meng X, Liu Y, Yang T, Zeng Y, Chen Y, Huang Y, Fang Z, Yang X, and Luo J

Subjects
agnps, focal adhesion, cardiac development, zebrafish, Medicine (General), R5-920
Abstract

Chunjiao Lu,&ast; Xuewei Wu,&ast; Xin Meng,&ast; Yi Liu, Ting Yang, Yan Zeng, Yang Chen, Yishan Huang, Zhou Fang, Xiaojun Yang, Juanjuan Luo Engineering Research Center of Key Technique for Biotherapy of Guangdong Province, Shantou University Medical College, Shantou, 515041, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xiaojun Yang; Juanjuan Luo, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, People’s Republic of China, Email yangx@stu.edu.cn; 15jjluo1@stu.edu.cnIntroduction: The potential toxic effects of wastewater discharges containing silver nanoparticles (AgNPs) and their release into aquatic ecosystems on aquatic organisms are becoming a major concern for environmental and human health. However, the potential risks of AgNPs to aquatic organisms, especially for cardiac development by Focal adhesion pathway, are still poorly understood.Methods: The cardiac development of various concentrations of AgNPs in zebrafish were examined using stereoscopic microscope. The expression levels of cardiac development-related genes were analyzed by qRT-PCR and Whole-mount in situ hybridization (WISH). In addition, Illumina high-throughput global transcriptome analysis was performed to explore the potential signaling pathway involved in the treatment of zebrafish embryos by AgNPs after 72 h.Results: We systematically investigated the cardiac developing toxicity of AgNPs on the embryos of zebrafish. The results demonstrated that 2 or 4 mg/L AgNPs exposure induces cardiac developmental malformations, such as the appearance of pericardial edema phenotype. In addition, after 72 h of exposure, the mRNA levels of cardiac development-related genes, such as myh7, myh6, tpm1, nppa, tbx5, tbx20, myl7 and cmlc1, were significantly lower in AgNPs-treated zebrafish embryos than in control zebrafish embryos. Moreover, RNA sequencing, KEGG (Kyoto Encyclopedia of Genes) and Genomes and GSEA (gene set enrichment analysis) of the DEGs (differentially expressed genes) between the AgNPs-exposed and control groups indicated that the downregulated DEGs were mainly enriched in focal adhesion pathways. Further investigations demonstrated that the mRNA levels of focal adhesion pathway-related genes, such as igf1ra, shc3, grb2b, ptk2aa, akt1, itga4, parvaa, akt3b and vcla, were significantly decreased after AgNPs treatment in zebrafish.Conclusion: Thus, our findings illustrated that AgNPs could impair cardiac development by regulating the focal adhesion pathway in zebrafish.Keywords: AgNPs, focal adhesion, cardiac development, zebrafish

Published
2024

8. Unveiling the Mechanism of Liangxue Siwu Decoction in Treating Rosacea Through Network Pharmacology and in-vitro Experimental Validation

Author

Zhong Y, Zhao Y, Meng X, Wang F, and Zhou L

Subjects
liangxue siwu decoction, molecular docking, network pharmacology, rosacea, skin inflammation, Pathology, RB1-214, Therapeutics. Pharmacology, RM1-950
Abstract

Yun Zhong,1– 3 Yufei Zhao,4 Xin Meng,2 Fan Wang,2 Lei Zhou1 1Department of Dermatology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China; 2Department of Dermatology, Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 3Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 4Department of Gastrointestinal Surgery, Laboratory of Surgery, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaCorrespondence: Lei Zhou, Department of Dermatology, the Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, 510630, People’s Republic of China, Tel +020-85253333, Fax +020-85253336, Email zhoulei53@mail.sysu.edu.cnBackground: Rosacea, a recurring dermatological disorder, demands effective therapeutic approaches. Traditional Chinese medicine, particularly Liangxue Siwu Decoction (LXSWD), has shown promise in managing inflammatory skin diseases, such as rosacea. This study focuses on uncovering LXSWD’s specific effects on the inflammatory symptoms of rosacea.Objective: Our research investigates LXSWD’s therapeutic effectiveness in rosacea treatment and delves into its underlying mechanisms.Methods: Network pharmacology was utilized to identify LXSWD’s key components and their targets in rosacea management, which were then validated by molecular docking. An in vivo rosacea-like model in LL-37-induced mice was developed, subdividing them into control, model, and LXSWD groups. The LXSWD group received oral administration (25.0 g/kg/day) for six days before model induction. Post-treatment evaluations included skin tissue analyses to verify our network pharmacology predictions.Results: Key active ingredients in LXSWD, such as quercetin, kaempferol, and luteolin, were identified alongside central target proteins like TNF and MMPs. Our molecular docking study confirmed the interactions between these ingredients and targets. Analyses through GO and KEGG pathways indicated LXSWD’s role in mitigating inflammation, particularly influencing the TNF and IL-17 pathways. LXSWD treatment in vivo markedly alleviated LL-37-induced symptoms in mice, showing a marked reduction in inflammatory cytokines (p < 0.05) and modulation of crucial genes (p < 0.05). These results, supported by immunofluorescence analysis and Western blot, underline the modulatory effects of LXSWD on MMPs, offering significant protection against rosacea’s inflammation alterations (p < 0.05).Conclusion: Integrating network pharmacology, molecular docking, and in vivo experiments, this study elucidates LXSWD’s potential mechanisms in rosacea treatment. It offers a novel theoretical framework for its clinical use in managing rosacea.Keywords: Liangxue siwu decoction, molecular docking, network pharmacology, rosacea, skin inflammation

Published
2024

9. Combined UTMD-Nanoplatform for the Effective Delivery of Drugs to Treat Renal Cell Carcinoma

Author

Dai T, Wang Q, Zhu L, Luo Q, Yang J, Meng X, Wang H, and Sun Z

Subjects
targeted therapy, deep-penetration, sonodynamic therapy, multimodal imaging, Medicine (General), R5-920
Abstract

Ting Dai,&ast; Qimeihui Wang,&ast; Lingyu Zhu, Qiang Luo, Jiayu Yang, Xia Meng, Hui Wang, Zhixia Sun Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Hui Wang; Zhixia Sun, Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, 130033, People’s Republic of China, Email whui66@jlu.edu.cn; sunzx@jlu.edu.cnIntroduction: The effective accumulation of nanoparticles (NPs) in the tumour area is an important goals of current nanotechnology research, and a targeted nanoplatform is an effective solution. So we designed a multifunctional sound-sensitive targeted NP that combines a sonosensitizer to enable precisely targeted, deep-penetration sonodynamic therapy (SDT) in combination with multimodal imaging for the diagnosis and monitoring of renal cell carcinoma (RCC).Methods: ZnPP@PP NPs (ZnPP@PLGA- PFP NPs) were prepared via a double emulsion method, and G250 was covalently attached to the NPs shell via the carbon diimide method. Physicochemical property tests were conducted on the ZnPP@G-PP NPs, including tests of particle size, potential distribution, encapsulation efficiency and drug loading capability. We assessed the targeting ability, the production of reactive oxygen species (ROS) and permeability of the NPs in vitro. Moreover, we evaluated the nanoparticle’s multimodal imaging capabilities and therapeutic ability against RCC, both in vitro and in vivo.Results: The Znpp@G-PP NPs were successfully constructed, and their general properties showed uniform particle size, negative potential and good stability. The nanoparticles were successfully loaded with ZnPP and connected with G250, showing tumor-specific targeting ability. Under LIFU irradiation, the nanoparticles produced 1O2 by SDT. For RCC, PA/US multi-modal imaging of Znpp@G-PP NPs provide diagnostic information and monitor therapies in real time in 786-O RCC xenografts, with good biocompatibility. With the UTMD, nanoparticles can be effectively targeted into the tumor cells and penetrate into the tumor interior, significantly improving the SDT effect. Experiments in vitro and in vivo showed that the combination of the nanoparticles and LIFU could suppress the tumor, and the therapeutic effect was confirmed by immunohistochemistry.Conclusion: ZnPP@G-PP NPs provide a promising theranostic strategy for RCC and a platform for further research on improving the efficacy of diagnosis and treatment.Keywords: targeted therapy, deep-penetration, sonodynamic therapy, multimodal imaging

Published
2024

10. Risk Factors Affecting the Outcomes of CT-Guided Radiofrequency Thermocoagulation of the T3 Sympathetic Nerve in the Treatment of Craniofacial Hyperhidrosis

Author

Fan H, Xu P, Zhang E, Meng X, Xia J, Fei Y, and Yao M

Subjects
ephidrosis, craniofacial hyperhidrosis, sympathetic radiofrequency thermocoagulation, Therapeutics. Pharmacology, RM1-950
Abstract

Hanrui Fan,1 Ping Xu,1 Enming Zhang,1 Xi Meng,2 Jianmei Xia,3 Yong Fei,3 Ming Yao3 1Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China; 2Zhejiang Sci-Tech University, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Anesthesiology and Pain, The First Hospital of Jiaxing, Jiaxing, Zhejiang, People’s Republic of ChinaCorrespondence: Yong Fei, Department of Anesthesiology and Pain, The First Hospital of Jiaxing, 1882 Zhong-Huan-South Road, Jiaxing, 314000, People’s Republic of China, Email jxfy6666662022@163.comBackground: Current studies mostly suggest that hyperhidrosis is caused by relative sympathetic hyperactivity. Sympathetic radiofrequency thermocoagulation is widely used in clinics. Previous studies have demonstrated that surgery at T3 is effective and safe compared with higher levels, so craniofacial hyperhidrosis in our hospital is selected to be treated at T3. However, some patients pursue repeat medical treatment due to an increase in hyperhidrosis at the original site after surgery. Previous studies have demonstrated the significance of Perfusion index (PI) value in the recurrence of palmar hyperhidrosis, but there is no relevant study on craniofacial hyperhidrosis.Methods: Clinical data from patients with craniofacial hyperhidrosis, who underwent T3 sympathetic radiofrequency thermocoagulation at Jiaxing First Hospital (Jiaxing, China) between January 1, 2018 and December 31, 2021, were analyzed. Recurrence in patients 1 year after surgery was recorded through a case search and telephone follow-up system that registered patient information. Clinical data were analyzed using binary logistic regression analysis to investigate risk factors associated with recurrence in patients with craniofacial hyperhidrosis 1 year after surgery.Results: Of 83 patients included in the present study, 34 (40%) experienced increased craniofacial sweating 1 year after surgery. Results of univariate logistic regression analysis revealed that computed tomography (CT) scan count, increase in pulse index (PI) at the fingertips, and differences in forehead temperature were potential risk factors for postoperative recurrence in patients with craniofacial hyperhidrosis (p< 0.2), and the results were consistent on both sides. Three potential risk factors were included in the multivariate logistic regression analysis and results revealed that the risk for recurrence was reduced by 48% (left side) and 67% (right side) for every 1 unit increase in PI value.Conclusion: A small increase in PI was an independent risk factor for recurrence of hyperhidrosis in patients with craniofacial hyperhidrosis after undergoing T3 sympathetic radiofrequency thermocoagulation.Keywords: ephidrosis, craniofacial hyperhidrosis, sympathetic radiofrequency thermocoagulation

Published
2024

11. A New Nanoplatform Under NIR Released ROS Enhanced Photodynamic Therapy and Low Temperature Photothermal Therapy for Antibacterial and Wound Repair

Author

Miao L, Xu Z, Sui J, Meng X, Huo S, Liu S, Chen M, Zheng Z, Cai X, and Zhang H

Subjects
infection-related wounds, magnesium-doped bioactive glass, photothermal therapy, photodynamic therapy, immunomodulation, Medicine (General), R5-920
Abstract

Licai Miao,1,&ast; Zihao Xu,1,&ast; Junhao Sui,1,&ast; Xiangyu Meng,1,&ast; Shicheng Huo,2 Shu Liu,1 Mengchen Chen,1 Zhong Zheng,1 Xiaobin Cai,3 Hao Zhang1 1Department of Orthopedics, Changhai Hospital Affiliated to the Navy Military Medical University, Shanghai, 200433, People’s Republic of China; 2Department of Orthopedic Surgery, Spine Center, Changzheng Hospital, Navy Medical University, Shanghai, 200003, People’s Republic of China; 3Department of Orthopedics Shanghai Tenth People’s Hospital Tongji University School of Medicine, Shanghai, 200072, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xiaobin Cai, Department of Orthopedics Shanghai Tenth People’s Hospital Tongji University School of Medicine, Shanghai, 200072, People’s Republic of China, Tel +8613122575295, Email caixbjn@163.com Hao Zhang Department of Orthopedics, Changhai Hospital Affiliated to the Navy Military Medical University, Tel +8613917856377, Email zhanghsmmu@126.comPurpose: Skin injury, often caused by physical or medical mishaps, presents a significant challenge as wound healing is critical to restore skin integrity and tissue function. However, external factors such as infection and inflammation can hinder wound healing, highlighting the importance of developing biomaterials with antibiotic and wound healing properties to treat infections and inflammation. In this study, a novel photothermal nanomaterial (MMPI) was synthesized for infected wound healing by loading indocyanine green (ICG) on magnesium-incorporated mesoporous bioactive glass (Mg-MBG) and coating its surface with polydopamine (PDA).Results: In this study, Mg-MBG and MMPI was synthesized via the sol-gel method and characterized it using various techniques such as scanning electron microscopy (SEM), the energy dispersive X-ray spectrometry (EDS) system and X-ray diffraction (XRD). The cytocompatibility of MMPI was evaluated by confocal laser scanning microscopy (CLSM), CCK8 assay, live/dead staining and F-actin staining of the cytoskeleton. The antibacterial efficiency was assessed using bacterial dead-acting staining, spread plate method (SPM) and TEM. The impact of MMPI on macrophage polarization was initially evaluated through flow cytometry, qPCR and ELISA. Additionally, an in vivo experiment was performed on a mouse model with skin excision infected. Histological analysis and RNA-seq analysis were utilized to analyze the in vivo wound healing and immunomodulation effect.Conclusion: Collectively, the new photothermal and photodynamic nanomaterial (MMPI) can achieve low-temperature antibacterial activity while accelerating wound healing, holds broad application prospects.Keywords: infection-related wounds, magnesium-doped bioactive glass, photothermal therapy, photodynamic therapy, immunomodulation

Published
2024

12. Highly Drug-Loaded Nanoaggregate Microparticles for Pulmonary Delivery of Cyclosporin A

Author

Huang Y, Tang H, Meng X, Liu D, Liu Y, Chen B, and Zou Z

Subjects
pulmonary drug delivery, dry powder inhalers, nanoaggregate microparticles, aerosol performance, pharmacodynamic study, inhalation toxicity, Medicine (General), R5-920
Abstract

Yongpeng Huang, Hui Tang, Xiangyan Meng, Dongxin Liu, Yanli Liu, Bo Chen, Zhiyun Zou State Key Laboratory of NBC Protection for Civilian, Beijing, People’s Republic of ChinaCorrespondence: Bo Chen; Zhiyun Zou, Email NBC_BoChen@163.com; zouzhiyun65@163.comIntroduction: Nanoparticles have the advantages of improving the solubility of poorly water-soluble drugs, facilitating the drug across biological barriers, and reducing macrophage phagocytosis in pulmonary drug delivery. However, nanoparticles have a small aerodynamic particle size, which makes it difficult to achieve optimal deposition when delivered directly to the lungs. Therefore, delivering nanoparticles to the lungs effectively has become a popular research topic.Methods: Nanoaggregate microparticles were used as a pulmonary drug delivery strategy for the improvement of the bioavailability of cyclosporine A (CsA). The nanoaggregate microparticles were prepared with polyvinyl pyrrolidone (PVP) as the excipient by combining the anti-solvent method and spray drying process. The physicochemical properties, aerodynamic properties, in vivo pharmacokinetics and inhalation toxicity of nanoaggregate microparticles were systematically evaluated.Results: The optimal nanoparticles exhibited mainly spherical shapes with the particle size and zeta potential of 180.52 nm and − 19.8 mV. The nanoaggregate microparticles exhibited irregular shapes with the particle sizes of less than 1.6 μm and drug loading (DL) values higher than 70%. Formulation NM-2 as the optimal nanoaggregate microparticles was suitable for pulmonary drug delivery and probably deposited in the bronchiole and alveolar region, with FPF and MMAD values of 89.62% and 1.74 μm. In addition, inhaled NM-2 had Cmax and AUC0-∞ values approximately 1.7-fold and 1.8-fold higher than oral cyclosporine soft capsules (Neoral®). The inhalation toxicity study suggested that pulmonary delivery of NM-2 did not result in lung function damage, inflammatory responses, or tissue lesions.Conclusion: The novel nanoaggregate microparticles for pulmonary drug delivery could effectively enhance the relative bioavailability of CsA and had great potential for clinical application. Keywords: pulmonary drug delivery, dry powder inhalers, nanoaggregate microparticles, aerosol performance, pharmacodynamic study, inhalation toxicity

Published
2024

13. Kasai Portoenterostomy, Successful Liver Transplantation, and Immunosuppressive Therapy for Biliary Atresia in a Female Baby: A Case Report

Author

Shan L, Wang F, Zhai D, Meng X, Liu J, and Lv X

Subjects
biliary atresia, kasai portoenterostomy, living-related liver transplantation, immunosuppressive drug, therapeutic drug monitoring, Pathology, RB1-214, Therapeutics. Pharmacology, RM1-950
Abstract

Liang Shan,1– 4 Fengling Wang,1 Dandan Zhai,1 Xiangyun Meng,1 Jianjun Liu,1 Xiongwen Lv2– 4 1Department of Pharmacy, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, Anhui, 230011, China; 2Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, Anhui, 230032, China; 3Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, Anhui, 230032, China; 4The Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, Anhui, 230032, ChinaCorrespondence: Jianjun Liu, Department of Pharmacy, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, Anhui, 230011, China, Tel/Fax +86 0551 62965335, Email Jianjun_liu2020@163.com Xiongwen Lv, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, Anhui, 230032, China, Tel/Fax +86 0551 65161000, Email Xiongwen_lv2019@163.comBackground: Biliary atresia (BA) is a severe neonatal progressive cholangiopathy of unknown etiology. A timely Kasai portoenterostomy (KPE) improves survival of the native liver in patients with BA, although liver transplantation remains the ultimate treatment for most (60%– 80%) patients. However, postoperative adverse effects of liver transplantation may be significant. In addition, patients require lifelong immunosuppressive therapy after liver transplantation.Case Summary: Here, we report a case of a newborn female baby (birthday: 10– 03-2018) with congenital BA (confirmed at 76 days of life) who survived KPE (first surgery at 85 days of life) and underwent successful living-related liver transplantation (LRLT) (second surgery at 194 days of life). Additionally, we reviewed the existing literature on BA. After KPE (at 85 days of life), the liver function of the baby did not improve, and the indicators of liver and kidney function showed a trend of aggravation, indicating that the liver function had been seriously damaged before KPE (at 85 days of life), demonstrating the urgent need for liver transplantation surgery. The female baby survived after part of her father’s liver was successfully transplanted into her body (at 194 days of life). The patient recovered successfully. No other diseases were found at the 4-year follow-up, and all indices of liver and kidney functions tended to be normal.Conclusion: This case highlights the following. Postoperative alkaline phosphatase was consistently above the normal range, although the reason for this was unclear; neither tacrolimus nor cyclosporine A has formulations designed specifically for infants, which does not meet the needs of clinical individualized medication, suggesting that these anti-rejection drugs are future development directions. Only one case of congenital BA has been found thus far in Hefei, and this case has extremely important reference significance for the prevention, treatment, and diagnosis of BA in Hefei, Anhui province. Keywords: biliary atresia, Kasai portoenterostomy, living-related liver transplantation, immunosuppressive drug, therapeutic drug monitoring

Published
2024

16. Direct Anterior Approach Total Hip Arthroplasty for Femoral Neck Fractures in the Lateral Position

Author

Wang X, Dai J, Wu Z, Yang Y, Zhang J, Meng X, Liu W, Fei W, and Wang J

Subjects
direct lateral approach, daa, femoral neck fractures, total hip arthroplasty, tha, hip function, postoperative rehabilitation, Geriatrics, RC952-954.6
Abstract

Xiaofei Wang,1,2,&ast; Jihang Dai,2,&ast; Zhimin Wu,1,2 Yuxia Yang,2 Jian Zhang,2 Xiangji Meng,1,2 Wenkang Liu,2 Wenyong Fei,2 Jingcheng Wang2 1The Graduate School, Dalian Medical University, Dalian, Liaoning, People’s Republic of China; 2Department of Orthopedics, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Wenyong Fei; Jingcheng Wang, Email sbydyx105@126.com; yzwangjingcheng@163.comObjective: To compare the clinical efficacy of artificial total hip arthroplasty(THA) for femoral neck fracture between direct anterior approach(DAA) in lateral position and posterior lateral approach(PLA).Methods: Comparison of 200 cases of patients who underwent THA collected between September 2019 and August 2021 was done. Incision length, intraoperative bleeding, operative time, difference in postoperative haemoglobin from preoperative levels, length of hospital stay, postoperative time to get off the floor, visual analogue score (VAS) for pain, preoperative and postoperative Harris scores for the hip, and measurements of the acetabular abduction angle and anterior acetabular tilt angle at 6 months postoperatively were collected, and all the cases were followed up for at least 2 years.Results: Compared with the PLA group, the DAA group had a shorter incision length, less intraoperative blood loss, less postoperative haemoglobin reduction compared with the preoperative period, a shorter hospital stay and an earlier first time to get off the floor after surgery, however, the comparison of operative times was not statistically significant; Patients in the DAA group had a lower VAS in the early postoperative period compared to PLA; Patients in the DAA group had higher hip Harris scores at 6 weeks and 6 months postoperatively; There was no significant difference in acetabular abduction angle and acetabular anterior tilt angle between the two groups at 6 months postoperatively.Conclusion: Compared to PLA, DAA in THA is minimally invasive, has less pain, less bleeding, earlier time out of bed, shorter hospital stay, better early hip function, faster rehabilitation, and better joint stability.Keywords: direct lateral approach, DAA, femoral neck fractures, total hip arthroplasty, THA, Hip function, postoperative rehabilitation

Published
2024

17. Rising Incidence of Acute Epiglottitis in Eastern China: An Eight-Year Retrospective Study and Its Association with the 24 Solar Terms

Author

Lu F, Wang Y, Miao F, Han C, and Meng X

Subjects
acute epiglottitis, 24 solar terms, seasonal variations, incidence, summer solstice, Medicine (General), R5-920
Abstract

Feng Lu,1,&ast; Yangyang Wang,2,&ast; Fangyu Miao,3 Chengzhou Han,2 Xiangming Meng2 1Department of Emergency Medicine, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People’s Hospital, Wuxi, 214187, People’s Republic of China; 2Department of Otolaryngology, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People’s Hospital, Wuxi, 214187, People’s Republic of China; 3Information Centre, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People’s Hospital, Wuxi, 214187, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xiangming Meng, Department of Otolaryngology, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People’s Hospital, 2 Zhanqian North Road, Luoshe Town, Huishan District, Wuxi, 214187, People’s Republic of China, Email xiangming_meng@hotmail.comPurpose: This study aimed to investigate the clinical characteristics of acute epiglottitis (AE) patients in East China and examine the correlation between the incidence of AE and the 24 solar terms (24 STs).Methods: A retrospective, observational study was conducted on patients diagnosed with AE between January 2014 and December 2021 at a single-center medical institution in East China. The clinical characteristics of patients with AE and their correlation with the 24 STs were investigated.Results: A total of 287 patients with AE were included in this study, among which there were 179 males (62.37%) and 108 females (37.63%), with a mean age of 47.79 ± 13.83 years (range 16– 87 years). Of these patients, 100 (34.84%) had at least one comorbidity and the most common comorbidities were hypertension, smoking and type 2 diabetes. The duration of hospitalization was 3 days (IQR, 1– 16 days). All patients, except for one who required tracheal intubation, were cured with intravenous antibiotic administration and the combined use of corticosteroids. The incidence of AE showed significant fluctuations between the 24 STs and the highest number of cases occurred during the Summer solstice (24 cases, 8.36%).Conclusion: The incidence of AE was seen to increase annually in this study. The main features of AE are sore throat, dysphagia, odynophagia and fever, which may be accompanied by inflammation in surrounding areas. A clear correlation exists between the incidence of AE and the fluctuations within the 24 STs, notably with the peak incidence observed during the Summer solstice, which approximately corresponds to June 21 to July 7 in the Gregorian calendar.Keywords: acute epiglottitis, 24 solar terms, seasonal variations, incidence, summer solstice

Published
2024

18. Serum Folate and Vitamin B12 Modify the Associations of N6AMT1 Genetic Variants with Gestational Diabetes Mellitus: A Cross-Sectional Study in Chinese Pregnant Women

Author

Guo G, Chen X, Zhang J, Meng X, Jia A, Xing X, Huang F, Zhang X, Liu J, Li S, and Zhang Q

Subjects
n6amt1, folate, vitamin b12, gene-nutrition interaction, gestational diabetes mellitus, Specialties of internal medicine, RC581-951
Abstract

Guanshuai Guo,1,2,&ast; Xi Chen,1,2,&ast; Jingran Zhang,1,2 Xiangmin Meng,3 Aifeng Jia,4 Xinli Xing,5 Fenglei Huang,6 Xumei Zhang,2,7 Juan Liu,8 Shuying Li,3,9 Qiang Zhang1,2 1Department of Occupational and Environmental Health, School of Public Health, Tianjin Medical University, Tianjin, People’s Republic of China; 2Tianjin Key Laboratory of Environment, Nutrition and Public Health, School of Public Health, Tianjin Medical University, Tianjin, People’s Republic of China; 3Department of Endocrinology, Tianjin Xiqing Hospital, Tianjin, People’s Republic of China; 4Department of Obstetrics and Gynecology, Tianjin Xiqing Hospital, Tianjin, People’s Republic of China; 5Department of Obstetrics and Gynecology, Women’s and Children’s Health Center of Dongchangfu District, Liaocheng, People’s Republic of China; 6Department of Reproductive Health, Women’s and Children’s Health Center of Dongchangfu District, Liaocheng, People’s Republic of China; 7Department of Nutrition and Food Science, School of Public Health, Tianjin Medical University, Tianjin, People’s Republic of China; 8Department of Biomedical Information and Library, Tianjin Medical University, Tianjin, People’s Republic of China; 9NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Shuying Li, Department of Endocrinology, Tianjin Xiqing Hospital, Tianjin, 300380, People’s Republic of China, Email lsy_tj2006@163.com Qiang Zhang, Department of Occupational and Environmental Health, School of Public Health, Tianjin Medical University, Tianjin, 300070, People’s Republic of China, Tel +86 022 83336633, Email qiangzhang@tmu.edu.cnPurpose: This study aimed to explore the association between N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) single nucleotide polymorphisms (SNPs) and gestational diabetes mellitus (GDM) and the modification of the relationship by folate and vitamin B12.Methods: A cross-sectional study involving 1303 pregnant women (262 GDM and 1041 non-GDM) was performed in Tianjin, China. Nine SNPs in N6AMT1 were genotyped, and serum folate, vitamin B12, and homocysteine (Hcy) levels were measured. The logistic regression models determined the odds ratios (ORs) for SNPs in N6AMT1 and the gene-nutrition interactions on GDM.Results: N6AMT1 rs7282280, rs1048546, and rs1997605 were related to GDM under the dominant model after adjusting for multiple covariates. Individuals carrying the N6AMT1 rs7282280 TC/TT genotypes had a lower risk of developing GDM, regardless of serum folate and vitamin B12 levels. However, rs1048546 TG/GG genotypes were associated with lower GDM risk when serum folate ≥ 6.0 ng/mL. Pregnancies with the risk genotypes in N6AMT1 and higher serum folate or lower vitamin B12 are more prone to GDM. The study also showed a statistically significant additive interaction between N6AMT1 rs1997605 GG genotypes and lower vitamin B12 (RERI: 2.54; 95% CI: 0.17, 4.92).Conclusion: SNPs in N6AMT1 were found to be associated with GDM, and serum folate and vitamin B12 levels can modify their associations.Keywords: N6AMT1, folate, vitamin B12, gene-nutrition interaction, gestational diabetes mellitus

Published
2024

20. Energetic electron precipitation driven by electromagnetic ion cyclotron waves from ELFIN's low altitude perspective

Author

Angelopoulos, V., Zhang, X. -J., Artemyev, A. V., Mourenas, D., Tsai, E., Wilkins, C., Runov, A., Liu, J., Turner, D. L., Li, W., Khurana, K., Wirz, R. E., Sergeev, V. A., Meng, X., Wu, J., Hartinger, M. D., Raita, T., Shen, Y., An, X., Shi, X., Bashir, M. F., Shen, X., Gan, L., Qin, M., Capannolo, L., Ma, Q., Russell, C. L., Masongsong, E. V., Caron, R., He, I., Iglesias, L., Jha, S., King, J., Kumar, S., Le, K., Mao, J., McDermott, A., Nguyen, K., Norris, A., Palla, A., Roosnovo, Tam, J., Xie, E., Yap, R. C., Ye, S., Young, C., Adair, L. A., Shaffer, C., Chung, M., Cruce, P., Lawson, M., Leneman, D., Allen, M., Anderson, M., Arreola-Zamora, M., Artinger, J., Asher, J., Branchevsky, D., Cliffe, M., Colton, K., Costello, C., Depe, D., Domae, B. W., Eldin, S., Fitzgibbon, L., Flemming, A., Frederick, D. M., Gilbert, A., Hesford, B., Krieger, R., Lian, K., McKinney, E., Miller, J. P., Pedersen, C., Qu, Z., Rozario, R., Rubly, M., Seaton, R., Subramanian, A., Sundin, S. R., Tan, A., Thomlinson, D., Turner, W., Wing, G., Wong, C., and Zarifian, A.

Subjects
Physics - Space Physics, Physics - Plasma Physics
Abstract

We review comprehensive observations of electromagnetic ion cyclotron (EMIC) wave-driven energetic electron precipitation using data from the energetic electron detector on the Electron Losses and Fields InvestigatioN (ELFIN) mission, two polar-orbiting low-altitude spinning CubeSats, measuring 50-5000 keV electrons with good pitch-angle and energy resolution. EMIC wave-driven precipitation exhibits a distinct signature in energy-spectrograms of the precipitating-to-trapped flux ratio: peaks at 0.5 MeV which are abrupt (bursty) with significant substructure (occasionally down to sub-second timescale). Multiple ELFIN passes over the same MLT sector allow us to study the spatial and temporal evolution of the EMIC wave - electron interaction region. Using two years of ELFIN data, we assemble a statistical database of 50 events of strong EMIC wave-driven precipitation. Most reside at L=5-7 at dusk, while a smaller subset exists at L=8-12 at post-midnight. The energies of the peak-precipitation ratio and of the half-peak precipitation ratio (our proxy for the minimum resonance energy) exhibit an L-shell dependence in good agreement with theoretical estimates based on prior statistical observations of EMIC wave power spectra. The precipitation ratio's spectral shape for the most intense events has an exponential falloff away from the peak (i.e., on either side of 1.45 MeV). It too agrees well with quasi-linear diffusion theory based on prior statistics of wave spectra. Sub-MeV electron precipitation observed concurrently with strong EMIC wave-driven 1MeV precipitation has a spectral shape that is consistent with efficient pitch-angle scattering down to 200-300 keV by much less intense higher frequency EMIC waves. These results confirm the critical role of EMIC waves in driving relativistic electron losses. Nonlinear effects may abound and require further investigation.

Published
2022
Full Text
View/download PDF

21. Construction of Precision sMDT Detector for ATLAS Muon Spectrometer Upgrade

Author

Amidei, D., Anderson, N., Chen, A., Carpenter, E., Cooperrider, L., Dai, T., Diehl, E., Ferretti, C., Guo, Y., Li, J., Meng, X., Nelson, K., Pillsbury, V., Salzer, E., Schwarz, T., Simpson, L., Wang, Z., Weaverdyck, C., Wei, C., Yang, Z., Yuan, M., Zhou, B., and Zhu, J.

Subjects
High Energy Physics - Experiment, Physics - Instrumentation and Detectors
Abstract

This paper describes the small-diameter monitored drift-tube detector construction at the University of Michigan as a contribution to the ATLAS Muon Spectrometer upgrade for the high-luminosity Large Hadron Collider at CERN. Measurements of the first 30 chambers built at Michigan show that the drift tube wire position accuracy meets the specification of 20 microns. The positions of the platforms for alignment and magnetic field sensors are all installed well within the required precision. The cosmic ray test measurements show single wire tracking resolution of 100 +- 7 microns with an average detection efficiency above 99 %. The infrastructure, tooling, techniques, and procedures for chamber production are described in detail. The results from the chamber quality control tests of the first 30 constructed chambers are reported., Comment: 35 pages, 41 figures

Published
2022
Full Text
View/download PDF

22. Potential scientific synergies in weak lensing studies between the CSST and Euclid space probes

Author

Liu, D. Z., Meng, X. M., Er, X. Z., Fan, Z. H., Kilbinger, M., Li, G. L., Li, R., Schrabback, T., Scognamiglio, D., Shan, H. Y., Tao, C., Ting, Y. S., Zhang, J., Cheng, S. H., Farrens, S., Fu, L. P., Hildebrandt, H., Kang, X., Kneib, J. P., Liu, X. K., Mellier, Y., Nakajima, R., Schneider, P., Starck, J. L., Wei, C. L., Wright, A. H., and Zhan, H.

Subjects
Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract

Aims. With the next generation of large surveys coming to the stage of observational cosmology soon, it is important to explore their potential synergies and to maximise their scientific outcomes. In this study, we aim to investigate the complementarity of the two upcoming space missions Euclid and the China Space Station Telescope (CSST), focusing on weak lensing (WL) cosmology. In particular, we analyse the photometric redshifts (photo-zs) and the galaxy blending effects. For Euclid, WL measurements suffer from chromatic PSF effects. For this, CSST can provide valuable information for Euclid to obtain more accurate PSF, and to calibrate the color and color-gradient biases for WL measurements. Methods. We create image simulations for different surveys, and quantify the photo-z performance. For blending analyses, we employ high-resolution HST/CANDELS data to mock Euclid, CSST, and an LSST-like survey. We analyse the blending fraction for different cases, and the blending effects on galaxy photometry. Furthermore, we demonstrate that CSST can provide a large enough number of high SNR multi-band galaxy images to calibrate the color-gradient biases for Euclid. Results. The sky coverage of Euclid lies entirely within the CSST footprint. The combination of Euclid with CSST data can be done more uniformly than with the various ground-based data. Our studies show that by combining Euclid and CSST, we can reach a photo-z precision of $\sigma_{\rm NMAD} \approx 0.04$, and an outlier fraction of $\eta\approx 2.4\%$. Because of the similarly high resolutions, the data combination of Euclid and CSST can be relatively straightforward for photometry. To include ground-based data, however, sophisticated deblending utilizing priors from high-resolution space data is demanded. The color-gradient biases for Euclid can be well calibrated to the level of 0.1% using galaxies from CSST deep survey., Comment: 18 pages, 19 figures and 2 tables. Accepted for publication in A&A

Published
2022
Full Text
View/download PDF

23. Energetic Electron Precipitation Driven by Electromagnetic Ion Cyclotron Waves from ELFIN's Low Altitude Perspective.

Author

Angelopoulos, V, Zhang, X-J, Artemyev, AV, Mourenas, D, Tsai, E, Wilkins, C, Runov, A, Liu, J, Turner, DL, Li, W, Khurana, K, Wirz, RE, Sergeev, VA, Meng, X, Wu, J, Hartinger, MD, Raita, T, Shen, Y, An, X, Shi, X, Bashir, MF, Shen, X, Gan, L, Qin, M, Capannolo, L, Ma, Q, Russell, CL, Masongsong, EV, Caron, R, He, I, Iglesias, L, Jha, S, King, J, Kumar, S, Le, K, Mao, J, McDermott, A, Nguyen, K, Norris, A, Palla, A, Roosnovo, A, Tam, J, Xie, E, Yap, RC, Ye, S, Young, C, Adair, LA, Shaffer, C, Chung, M, Cruce, P, Lawson, M, Leneman, D, Allen, M, Anderson, M, Arreola-Zamora, M, Artinger, J, Asher, J, Branchevsky, D, Cliffe, M, Colton, K, Costello, C, Depe, D, Domae, BW, Eldin, S, Fitzgibbon, L, Flemming, A, Frederick, DM, Gilbert, A, Hesford, B, Krieger, R, Lian, K, McKinney, E, Miller, JP, Pedersen, C, Qu, Z, Rozario, R, Rubly, M, Seaton, R, Subramanian, A, Sundin, SR, Tan, A, Thomlinson, D, Turner, W, Wing, G, Wong, C, and Zarifian, A

Subjects
Electromagnetic ion cyclotron waves, Magnetosphere, Plasma waves, Radiation belts, Relativistic electron precipitation, Whistler-mode chorus, Astronomical and Space Sciences, Astronomy & Astrophysics
Abstract

We review comprehensive observations of electromagnetic ion cyclotron (EMIC) wave-driven energetic electron precipitation using data collected by the energetic electron detector on the Electron Losses and Fields InvestigatioN (ELFIN) mission, two polar-orbiting low-altitude spinning CubeSats, measuring 50-5000 keV electrons with good pitch-angle and energy resolution. EMIC wave-driven precipitation exhibits a distinct signature in energy-spectrograms of the precipitating-to-trapped flux ratio: peaks at >0.5 MeV which are abrupt (bursty) (lasting ∼17 s, or ΔL∼0.56) with significant substructure (occasionally down to sub-second timescale). We attribute the bursty nature of the precipitation to the spatial extent and structuredness of the wave field at the equator. Multiple ELFIN passes over the same MLT sector allow us to study the spatial and temporal evolution of the EMIC wave - electron interaction region. Case studies employing conjugate ground-based or equatorial observations of the EMIC waves reveal that the energy of moderate and strong precipitation at ELFIN approximately agrees with theoretical expectations for cyclotron resonant interactions in a cold plasma. Using multiple years of ELFIN data uniformly distributed in local time, we assemble a statistical database of ∼50 events of strong EMIC wave-driven precipitation. Most reside at L∼5-7 at dusk, while a smaller subset exists at L∼8-12 at post-midnight. The energies of the peak-precipitation ratio and of the half-peak precipitation ratio (our proxy for the minimum resonance energy) exhibit an L-shell dependence in good agreement with theoretical estimates based on prior statistical observations of EMIC wave power spectra. The precipitation ratio's spectral shape for the most intense events has an exponential falloff away from the peak (i.e., on either side of ∼1.45 MeV). It too agrees well with quasi-linear diffusion theory based on prior statistics of wave spectra. It should be noted though that this diffusive treatment likely includes effects from nonlinear resonant interactions (especially at high energies) and nonresonant effects from sharp wave packet edges (at low energies). Sub-MeV electron precipitation observed concurrently with strong EMIC wave-driven >1 MeV precipitation has a spectral shape that is consistent with efficient pitch-angle scattering down to ∼ 200-300 keV by much less intense higher frequency EMIC waves at dusk (where such waves are most frequent). At ∼100 keV, whistler-mode chorus may be implicated in concurrent precipitation. These results confirm the critical role of EMIC waves in driving relativistic electron losses. Nonlinear effects may abound and require further investigation.

Published
2023

25. Diagnostic Value of Carotid Plaque Assessment with AIS Based on Quantitative Parameters of Dual-Layer Detector Spectral CT

Author

Meng X, Li F, Wu W, and Wu J

Subjects
ischemic stroke, carotid plaque, spectal ct, effective atomic number, iodine density values, anhydrous iodine values；electron density, Medicine (General), R5-920
Abstract

Xiaoying Meng,1,2 Fei Li,2 Wenpei Wu,3 Juncang Wu1,2 1Department of Neurology, Hefei Hospital Affiliated to Anhui Medical University (Hefei Second People’s Hospital), Hefei, Anhui, 230011, People’s Republic of China; 2The Fifth Clinical School of Medicine, Anhui Medical University, Hefei, Anhui, 230032, People’s Republic of China; 3Department of Neurology, Hefei Second People’s Hospital Affiliated to Bengbu Medical College, Hefei, Anhui, 230011, People’s Republic of ChinaCorrespondence: Juncang Wu, Department of Neurology, Hefei Hospital Affiliated to Anhui Medical University (Hefei Second People’s Hospital), Hefei, Anhui, 230011, People’s Republic of China, Email wujuncang126@126.comPurpose: To investigate the quantitative assessment of carotid plaque by each parameter of dual-layer detector spectral CT and its diagnostic value in patients with acute cerebral infarction.Patients and Methods: Eighty-three patients with carotid atherosclerotic plaques who underwent spectral CT scanning were retrospectively included. Forty-two patients with acute ischaemic stroke (AIS) were included in the study group, and 41 patients without AIS were included in the control group. We compared the detection of carotid plaques in the two groups and the differences in the spectral quantitative parameters of the plaques in the two groups, and their diagnostic efficacy was obtained.Results: The detection rate of carotid plaques in the AIS group was higher than that in the non-AIS group (p< 0.05); the carotid plaques in the AIS group mainly consisted of non-calcified plaques, while those in the non-AIS group mainly consisted of calcified plaques. The effective atomic number (Zeff), slope of the energy spectrum curve (λH), electron density (ED), and iodine-no-water value of the carotid plaques in the AIS group were lower than those in the non-AIS (p< 0.05). For the differentiation of the carotid plaques in the AIS group from those in the non-AIS group, the area under the curve (AUC) of Zeff amounted to 0.637 (cut-off value: 11.865; sensitivity: 72.5%; specificity: 56.2%), the AUC of λH amounted to 0.628 (cut-off value: 19.56; sensitivity: 76.3%; specificity: 51.6%), and that for ED amounted to 0.624 (cut-off value: 110.45; sensitivity: 60.0%; specificity: 64.1%), AUC of iodine-no-water value amounted to 0.645 (cut-off value: 9.125; sensitivity: 61.3%; specificity: 65.6%).Conclusion: In summary, the quantitative parameters of dual-layer detector spectral CT can be used to assess plaque stability and have certain value in the diagnosis of AIS. The quantitative parameters can effectively differentiate carotid plaques in AIS and non-AIS patients.Keywords: ischemic stroke, carotid plaque, spectral CT, effective atomic number, iodine density values, anhydrous iodine values, electron density

Published
2024

26. GNPNAT1 is a Biomarker That Predicts a Poor Prognosis of Breast Cancer

Author

Zhou Y, Xue W, Meng X, Bhandari A, Zeng H, KC R, Hirachan S, and Xia E

Subjects
gnpnat1, biomarker, breast cancer, diagnosis, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Yuying Zhou,1,&ast; Wu Xue,2,&ast; Xinyu Meng,2,&ast; Adheesh Bhandari,2,3,&ast; Hanqian Zeng,4 Rajan KC,5 Suzita Hirachan,6 Erjie Xia2 1Department of Oncology and Hematology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang, People’s Republic of China; 2Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 3Department of Surgery, Breast and Thyroid Unit, Primera Hospital, Kathmandu, Nepal; 4Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang Province, People’s Republic of China; 5Central Department of Zoology, Tribhuvan University, Kirtipur, Kathmandu, Nepal; 6Department of General Surgery, Breast and Thyroid Unit, Tribhuvan University, Teaching Hospital, Kathmandu, Nepal&ast;These authors contributed equally to this workCorrespondence: Erjie Xia, Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China, Tel +86 577 5557 8527, Email erjiexia1@126.com Yuying Zhou, Department of Oncology and Hematology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang, People’s Republic of China, Tel +8615757194239, Email yuying_ne@163.comBackground: Breast cancer (BC) is increasingly becoming the primary reason for death in women, which sounded the alarm. Thus, finding a novel management target for BC is imminent.Materials and Methods: The data on gene expression and clinicopathological characteristics were downloaded from The Cancer Genome Atlas (TCGA). The expression of GNPNAT1 in 40 paired breast cancer and adjacent tissues was measured by quantitative real-time polymerase chain reaction (qRT-PCR). Univariate and Multivariate logistic regression methodology was applied to analyze the prognostic factors for lymph node metastasis (LNM). Based on the status of breast cancer-relative receptors, patients were distributed into six groups, and then the Kaplan-Meier survival analysis with a Log rank test was applied to investigate the involvement among the expression of GNPNAT1 and overall survival (OS).Results: We found higher expression of GNPNAT1 was connected with poor survival in breast cancer by COX regulation analysis. GO, KEGG, and GSEA analysis prompted that GNPNAT1 was connected with the defense mechanism of cells, cell proliferation, and division. Immunization infiltration analysis showed that high GNPNAT1 was negatively connected with 16 immunization infiltration cell types and positively connected with four immunization infiltration cell types.Conclusion: As a whole, our results indicated that GNPNAT1 might be a probable biomarker for diagnosis and prognosis in breast cancer.Keywords: GNPNAT1, biomarker, breast cancer, diagnosis, prognosis

Published
2024

27. Prognostic Significance of Uric Acid Levels in Intracerebral Hemorrhage Patients

Author

Wu W, Geng Z, Wu A, Chen X, Meng X, Zhang Q, Tan Z, Yue H, and Wu J

Subjects
intracerebral hemorrhage, uric acid, oxidative stress, follow-up, nonlinear relationship, prognosis, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Wenpei Wu,1,2,&ast; Zhi Geng,3– 5,&ast; Aimei Wu,2,&ast; Xinyi Chen,6,7 Xiaoying Meng,2 Qianyun Zhang,2 Zheng Tan,2 Hong Yue,2 Juncang Wu1,2 1Department of Neurology, Hefei Second People’s Hospital Affiliated to Bengbu Medical University, Hefei, Anhui, 230011, People’s Republic of China; 2Department of Neurology, Hefei Second People’s Hospital, Hefei, Anhui, 230011, People’s Republic of China; 3Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 4Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, People’s Republic of China; 5Collaborative Innovation Centre of Neuropsychiatric Disorder and Mental Health, Hefei, 230000, People’s Republic of China; 6Department of Neurology, Hefei Hospital Affiliated to Anhui Medical University (Hefei Second People’s Hospital), Hefei, Anhui, 230011, People’s Republic of China; 7The Fifth Clinical School of Medicine, Anhui Medical University, Hefei, Anhui, 230011, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Juncang Wu; Hong Yue, Intersection of Guangde Road and Leshui Road, Hefei, Anhui, 230011, People’s Republic of China, Tel/Fax +86 551 13956076148 ; +86 551 18949855780, Email wujuncang126@126.com; yuehong01@foxmail.comBackground and Purpose: The role of serum uric acid (UA) level in patients suffering from stroke remains controversial. Our aim was to investigate the effect of UA level on clinical outcomes in patients with intracerebral hemorrhage (ICH).Methods: In the retrospective cohort study, we analyzed data from 250 patients with intracerebral hemorrhage (85 women and 165 men) to investigate the difference in UA levels between patients with a good prognosis and those with a poor prognosis. Additionally, we analyzed the impact of UA levels on the risk of short-time prognosis of ICH patients.Results: Patients with a good prognosis presented with significantly lower levels of UA (348.71 ± 84.97 μmol/L) than those with poor prognosis (393.06 ± 148.46 μmol/L). Furthermore, multivariate logistic regression model demonstrated that a high UA level was a likely risk factor for worse prognosis among patients suffering in ICH (odds ratio [95% confidence interval], 1.006 [1.0012, 1.0108]; P = 0.015). Additionally, UA has a threshold effect value of 363.9 μmol/L and was presented in levels that were in a nonlinear relationship with incidence rate of short-time prognosis outcome of ICH patients.Conclusion: Our findings indicate that higher UA levels can increase the risk of poor clinical prognosis in patients with ICH and high UA levels are not conductive to the clinical prognosis of patients with ICH. These findings provide a new perspective on the treatment and prevention of ICH.Keywords: intracerebral hemorrhage, uric acid, oxidative stress, follow-up, nonlinear relationship, prognosis

Published
2024

28. Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression

Author

Wang M, Lan S, Zhang W, Jin Q, Du H, Sun X, He L, Meng X, Su L, and Liu G

Subjects
copper, carbon quantum dots, breast cancer, oxidative stress, mapk signaling pathway, Medicine (General), R5-920
Abstract

Mengqi Wang,1,&ast; Shuting Lan,1,&ast; Wenqi Zhang,1,&ast; Qin Jin,2 Hua Du,3 Xiaomei Sun,1 Lijun He,1 Xiangyun Meng,1 Liya Su,1 Gang Liu1 1Key Laboratory of Medical Cell Biology, Department of Achievement Transformation, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China; 2Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, People’s Republic of China; 3Department of Pathology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Gang Liu, Email 20190043@immu.edu.cnIntroduction: The anti-cancer potency of copper-doped carbon quantum dots (Cu-CDs) against breast cancer progression needs more detailed investigations.Methods: With urea and ethylene glycol applied as carbon sources and copper sulfate used as a reactive dopant, Cu-CDs were synthesized in the current study by a one-step hydrothermal synthesis method, followed by the characterization and biocompatibility evaluations of Cu-CDs. Subsequently, the anti-cancer potency of Cu-CDs against breast cancer progression was confirmed by these biochemical, molecular, and transcriptomic assessments, including viability, proliferation, migration, invasion, adhesion, clonogenicity, cell cycle distribution, apoptosis, redox homeostasis, and transcriptomic assays of MDA-MB-231 cells.Results: The biocompatibility of Cu-CDs was confirmed based on the non-significant changes in the pathological and physiological parameters in the Cu-CDs treated mice, as well as the noncytotoxic effect of Cu-CDs on normal cells. Moreover, the Cu-CDs treatments not only decreased the viability, proliferation, migration, invasion, adhesion, and clonogenicity of MDA-MB-231 cells but also induced the redox imbalance, cell cycle arrest, and apoptosis of MDA-MB-231 cells via ameliorating the mitochondrial dysfunctions and regulating the MAPK signaling pathway.Conclusion: Our findings confirmed the biosafety and excellent anti-cancer potency of Cu-CDs against breast cancer progression by tapping into mechanisms that disrupt malignant behaviors and oxidative homeostasis of breast cancer cells.Keywords: copper, carbon quantum dots, breast cancer, oxidative stress, MAPK signaling pathway

Published
2024

29. The Translation, Culture-Adaptation and Psychometric Evaluation of the Cardiac Rehabilitation Barriers Scale Among Chinese Older Population

Author

Zhang S, Yu M, Zhang Y, Liang C, Hu D, Wang DW, and Meng X

Subjects
cardiac rehabilitation, internal reliability, cross-cultural adaptation, exploratory factor analysis, confirmatory factor analysis., Medicine (General), R5-920
Abstract

Sisi Zhang,1 Miao Yu,2 Yu Zhang,2 Conying Liang,2 Dayi Hu,1 Dao Wen Wang,1 Xiaoping Meng2 1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2Department of Cardiology and Cardiac Rehabilitation, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, 130000, People’s Republic of ChinaCorrespondence: Xiaoping Meng, Department of Cardiology and Cardiac Rehabilitation, Affiliated Hospital of Changchun University of Chinese Medicine, &num;1473 Gongnong Road, Chaoyang District, Changchun, 130000, People’s Republic of China, Email xiopingmeng@126.comPurpose: This study aimed to translate and cross-culturally adapt the cardiac rehabilitation barriers scale to the Chinese, and examine its reliability and validity among the older population.Methods: An approach comprising translation, cultural adaptation, reliability, and validity examination in the Chinese version was conducted in two hospitals in Jilin, China. The t-tests were used to compare the sex differences between each item. Participants included Chinese individuals > 60 who were eligible for the cardiac rehabilitation program.Results: In total, 325 participants completed the questionnaire with an average age of 61.23 ± 9.68 years. The item-total correlations were 0.432 to 0.678. Factor analysis of CRBS-C (Kaiser Meyer Olkin = 0.867, Bartlett’s test p = 0.000) revealed four factors: logistical factors, comorbidities/functional status, perceived need/healthcare factors, and work/time conflict. The confirmatory factor analysis (CFA) indicated a good model fit (χ 2/df = 1.84, RMSEA = 0.051, CFI = 0.953, TLI = 0.945, SRMR=0.046). Cronbach’s alpha was 0.88 for the scale, ranging from 0.801 to 0.88 for each item, which indicates the internal reliability was acceptable.Conclusion: The Chinese version of the CRRS has acceptable reliability and validity in the Chinese elderly population.Keywords: cardiac rehabilitation, internal reliability, cross-cultural adaptation, exploratory factor analysis, confirmatory factor analysis

Published
2024

30. Decline in Working Memory in Stable Schizophrenia May Be Related to Attentional Impairment: Mediating Effects of Negative Symptoms, a Cross-Sectional Study

Author

Du N, Meng X, Li J, Shi L, and Zhang X

Subjects
stable schizophrenia；working memory；attention；negative symptom；intermediary effect, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Nan Du,1,2 Xiaojing Meng,1,2 Jingwei Li,2 Li Shi,2 Xulai Zhang1,2 1Affiliated Psychological Hospital of Anhui Medical University, Hefei Fourth People’s Hospital, Hefei, 230022, People’s Republic of China; 2Anhui Clinical Center for Mental and Psychological Diseases, Hefei Fourth People’s Hospital, Hefei, 230022, People’s Republic of ChinaCorrespondence: Xulai Zhang, Hefei Fourth People’s Hospital, 316 Mei shan Road, Hefei, Anhui, 230032, People’s Republic of China, Email xulaizhang@163.comBackground: Schizophrenia (SCZ) is a severe mental illness, Cognitive deficits and negative symptoms (NS) are prevalent in individuals with SCZ and are crucial indicators of functional recovery. It is well known that cognitive symptoms and negative symptoms are interrelated and that negative symptoms can affect the ability to take cognitive tests. However, the specific relationship between attention, working memory (WM), and NS in stable SCZ remains unclear. This study aims to explore these associations and provide valuable insights for the subsequent treatment of SCZ.Methods: We conducted a comprehensive assessment of 145 patients with stable SCZ using the Chinese Brief Neurocognitive Suite of Tests (C-BCT) and the Positive and Negative Symptom Scale (PANSS).Results: Patients with abnormal cognition exhibited significantly higher PANSS total scores, cognitive symptom scores, and NS than those with normal cognition (P< 0.05). Pearson’s correlation analysis revealed significant positive correlations between digital breadth(DB) and continuous operation(CO) (r=0.389, P< 0.001), as well as a significant negative correlation between DB and NS (r=− 0.291, P< 0.001). Moreover, CO showed a negative correlation with NS (r=− 0.173, P< 0.05). However, no significant correlations were found between the digital breadth-anterograde score and CO or NS (r=0.148, P> 0.05; r=− 0.068, P> 0.05). Notably, NS were identified as a mediator in the relationship between attention and WM (effect size=0.024).Conclusion: Our findings highlight significant associations between WM, attention, and NS in individuals with stable SCZ. Moreover, attention not only directly impacts WM but also indirectly influences it through NS. Addressing cognitive deficits and NS in the treatment of SCZ may lead to improved overall outcomes for affected individuals.Keywords: stable schizophrenia, working memory, attention, negative symptom, intermediary effect

Published
2024

31. Relationship Between Dermoscopic Capillary-Related Features of the Auricle and Earlobe and Rosacea Subtype and Disease Severity: A Cross-Sectional Analysis

Author

Zhang Y, Pan R, Gu D, Meng X, Liu T, and Xu Y

Subjects
skin conditions, ear, dermoscopy, blood vessels, Dermatology, RL1-803
Abstract

Yue Zhang, Ruoxin Pan, Duoduo Gu, Xiaoqi Meng, Tingwei Liu, Yang Xu Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, 210029, People’s Republic of ChinaCorrespondence: Yang Xu, Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, Jiangsu Province, 210029, People’s Republic of China, Tel/Fax +86-13851856794, Email yangxu@njmu.edu.cnBackground and Aim: Clinical manifestations of rosacea include transient or persistent facial erythema, telangiectasia, papules, and pustules. The existing assessment tools primarily evaluate the facial area to assess the severity of rosacea. However, in addition to the face, telangiectasia, erythema, and flushing can occur in the ear. Here, we investigated the correlation between the dermoscopic characteristics of capillaries in the earlobe and auricle and the types and severity of rosacea.Materials and Methods: Experienced dermatologists evaluated the clinical type, medical history, severity, and distribution pattern of facial erythema. The clinical severity of rosacea was assessed using the standard grading system (SGS), clinician’s erythema assessment (CEA), and investigator’s global assessment (IGA). Relationships of the clinical types and severity with the dermoscopic characteristics of capillaries in the earlobe and auricle were further analyzed.Results: In total, 145 patients with rosacea were enrolled in this study. We found that SGS, CEA, and IGA correlated well with the dermoscopic features of capillaries in the earlobe (R = 0.357, 0.357, and 0.314, respectively) (p < 0.001) and auricle (R = 0.423, 0.443, and 0.374, respectively) (p < 0.001). However, there was no significant correlation between the features and types of rosacea.Conclusion: The dermoscopic characteristics of capillaries in the earlobe and auricle can be used as indicators of the clinical severity of rosacea, regardless of the clinical subtype.Keywords: skin conditions, ear, dermoscopy, blood vessels

Published
2023

32. Potential PeVatron supernova remnant G106.3+2.7 seen in the highest-energy gamma rays

Author

Amenomori, M., Bao, Y. W., Bi, X. J., Chen, D., Chen, T. L., Chen, W. Y., Chen, Xu, Chen, Y., Cirennima, Cui, S. W., Danzengluobu, Ding, L. K., Fang, J. H., Fang, K., Feng, C. F., Feng, Zhaoyang, Feng, Z. Y., Gao, Qi, Gou, Q. B., Guo, Y. Q., Guo, Y. Y., He, H. H., He, Z. T., Hibino, K., Hotta, N., Hu, Haibing, Hu, H. B., Huang, J., Jia, H. Y., Jiang, L., Jin, H. B., Kasahara, K., Katayose, Y., Kato, C., Kato, S., Kawata, K., Kihara, W., Ko, Y., Kozai, M., Labaciren, Le, G. M., Li, A. F., Li, H. J., Li, W. J., Lin, Y. H., Liu, B., Liu, C., Liu, J. S., Liu, M. Y., Liu, W., Lou, Y. -Q., Lu, H., Meng, X. R., Munakata, K., Nakada, H., Nakamura, Y., Nanjo, H., Nishizawa, M., Ohnishi, M., Ohura, T., Ozawa, S., Qian, X. L., Qu, X. B., Saito, T., Sakata, M., Sako, T. K., Shao, J., Shibata, M., Shiomi, A., Sugimoto, H., Takano, W., Takita, M., Tan, Y. H., Tateyama, N., Torii, S., Tsuchiya, H., Udo, S., Wang, H., Wu, H. R., Xue, L., Yamamoto, Y., Yang, Z., Yokoe, Y., Yuan, A. F., Zhai, L. M., Zhang, H. M., Zhang, J. L., Zhang, X., Zhang, X. Y., Zhang, Y., Zhang, Yi, Zhang, Ying, Zhao, S. P., Zhaxisangzhu, and Zhou, X. X.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

Cosmic rays (protons and other atomic nuclei) are believed to gain energies of petaelectronvolts (PeV) and beyond at astrophysical particle accelerators called 'PeVatrons' inside our Galaxy. Although a characteristic feature of a PeVatron is expected to be a hard gamma-ray energy spectrum that extends beyond 100 teraelectronvolts (TeV) without a cutoff, none of the currently known sources exhibits such a spectrum due to the low maximum energy of accelerated cosmic rays or insufficient detector sensitivity around 100 TeV. Here we report the observation of gamma-ray emission from the supernova remnant G106.3+2.7 above 10 TeV. This work provides flux data points up to and above 100 TeV and indicates that the very-high-energy gamma-ray emission above 10 TeV is well correlated with a molecular cloud rather than the pulsar PSR J2229+6114. Regarding the gamma-ray emission mechanism of G106.3+2.7, this morphological feature appears to favor a hadronic origin via the {\pi}0 decay caused by accelerated relativistic protons over a leptonic one via the inverse-Compton scattering by relativistic electrons. Furthermore, we point out that an X-ray flux upper limit on the synchrotron spectrum would provide important information to firmly establish the hadronic scenario as the mechanism of particle acceleration at the source., Comment: Published in Nature Astronomy

Published
2021
Full Text
View/download PDF

33. Gamma-ray Observation of the Cygnus Region in the 100 TeV Energy Region

Author

Amenomori, M., Bao, Y. W., Bi, X. J., Chen, D., Chen, T. L., Chen, W. Y., Chen, Xu, Chen, Y., Cirennima, Cui, S. W., Danzengluobu, Ding, L. K., Fang, J. H., Fang, K., Feng, C. F., Feng, Zhaoyang, Feng, Z. Y., Gao, Qi, Gomi, A., Gou, Q. B., Guo, Y. Q., Guo, Y. Y., He, H. H., He, Z. T., Hibino, K., Hotta, N., Hu, Haibing, Hu, H. B., Huang, J., Jia, H. Y., Jiang, L., Jiang, P., Jin, H. B., Kasahara, K., Katayose, Y., Kato, C., Kato, S., Kawata, K., Kozai, M., Kurashige, D., Labaciren, Le, G. M., Li, A. F., Li, H. J., Li, W. J., Li, Y., Lin, Y. H., Liu, B., Liu, C., Liu, J. S., Liu, L. Y., Liu, M. Y., Liu, W., Liu, X. L., Lou, Y. -Q., Lu, H., Meng, X. R., Munakata, K., Nakada, H., Nakamura, Y., Nakazawa, Y., Nanjo, H., Ning, C. C., Nishizawa, M., Ohnishi, M., Ohura, T., Okukawa, S., Ozawa, S., Qian, L., Qian, X., Qian, X. L., Qu, X. B., Saito, T., Sakata, M., Sako, T., Sako, T. K., Shao, J., Shibata, M., Shiomi, A., Sugimoto, H., Takano, W., Takita, M., Tan, Y. H., Tateyama, N., Torii, S., Tsuchiya, H., Udo, S., Wang, H., Wang, Y. P., Wangdui, Wu, H. R., Wu, Q., Xu, J. L., Xue, L., Yamamoto, Y., Yang, Z., Yao, Y. Q., Yin, J., Yokoe, Y., Yu, N. P., Yuan, A. F., Zhai, L. M., Zhang, C. P., Zhang, H. M., Zhang, J. L., Zhang, X., Zhang, X. Y., Zhang, Y., Zhang, Yi, Zhang, Ying, Zhao, S. P., Zhaxisangzhu, and Zhou, X. X.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

We report observations of gamma-ray emissions with energies in the 100 TeV energy region from the Cygnus region in our Galaxy. Two sources are significantly detected in the directions of the Cygnus OB1 and OB2 associations. Based on their positional coincidences, we associate one with a pulsar PSR J2032+4127 and the other mainly with a pulsar wind nebula PWN G75.2+0.1 with the pulsar moving away from its original birthplace situated around the centroid of the observed gamma-ray emission. This work would stimulate further studies of particle acceleration mechanisms at these gamma-ray sources., Comment: Accepted for publication in the Physical Review Letters

Published
2021
Full Text
View/download PDF

35. Erratum to: Search for exclusive Higgs and Z boson decays to ϕγ and ργ with the ATLAS detector

Author

Aaboud, M., Aad, G., Abbott, B., Abdinov, O., Abeloos, B., Abidi, S. H., AbouZeid, O. S., Abraham, N. L., Abramowicz, H., Abreu, H., Abreu, R., Abulaiti, Y., Acharya, B. S., Adachi, S., Adamczyk, L., Adelman, J., Adersberger, M., Adye, T., Affolder, A. A., Afik, Y., Agatonovic-Jovin, T., Agheorghiesei, C., Aguilar-Saavedra, J. A., Ahlen, S. P., Ahmadov, F., Aielli, G., Akatsuka, S., Akerstedt, H., Åkesson, T. P. A., Akilli, E., Akimov, A. V., Alberghi, G. L., Albert, J., Albicocco, P., Alconada Verzini, M. J., Alderweireldt, S. C., Aleksa, M., Aleksandrov, I. N., Alexa, C., Alexander, G., Alexopoulos, T., Alhroob, M., Ali, B., Aliev, M., Alimonti, G., Alison, J., Alkire, S. P., Allbrooke, B. M. M., Allen, B. W., Allport, P. P., Aloisio, A., Alonso, A., Alonso, F., Alpigiani, C., Alshehri, A. A., Alstaty, M. I., Alvarez Gonzalez, B., Álvarez Piqueras, D., Alviggi, M. G., Amadio, B. T., Amaral Coutinho, Y., Amelung, C., Amidei, D., Amor Dos Santos, S. P., Amoroso, S., Amundsen, G., Anastopoulos, C., Ancu, L. S., Andari, N., Andeen, T., Anders, C. F., Anders, J. K., Anderson, K. J., Andreazza, A., Andrei, V., Angelidakis, S., Angelozzi, I., Angerami, A., Anisenkov, A. V., Anjos, N., Annovi, A., Antel, C., Antonelli, M., Antonov, A., Antrim, D. J., Anulli, F., Aoki, M., Aperio Bella, L., Arabidze, G., Arai, Y., Araque, J. P., Araujo Ferraz, V., Arce, A. T. H., Ardell, R. E., Arduh, F. A., Arguin, J-F., Argyropoulos, S., Arik, M., Armbruster, A. J., Armitage, L. J., Arnaez, O., Arnold, H., Arratia, M., Arslan, O., Artamonov, A., Artoni, G., Artz, S., Asai, S., Asbah, N., Ashkenazi, A., Asquith, L., Assamagan, K., Astalos, R., Atkinson, M., Atlay, N. B., Augsten, K., Avolio, G., Axen, B., Ayoub, M. K., Azuelos, G., Baas, A. E., Baca, M. J., Bachacou, H., Bachas, K., Backes, M., Bagnaia, P., Bahmani, M., Bahrasemani, H., Baines, J. T., Bajic, M., Baker, O. K., Bakker, P. J., Baldin, E. M., Balek, P., Balli, F., Balunas, W. K., Banas, E., Bandyopadhyay, A., Banerjee, Sw., Bannoura, A. A. E., Barak, L., Barberio, E. L., Barberis, D., Barbero, M., Barillari, T., Barisits, M.-S., Barkeloo, J. T., Barklow, T., Barlow, N., Barnes, S. L., Barnett, B. M., Barnett, R. M., Barnovska-Blenessy, Z., Baroncelli, A., Barone, G., Barr, A. J., Barranco Navarro, L., Barreiro, F., Barreiro Guimarães da Costa, J., Bartoldus, R., Barton, A. E., Bartos, P., Basalaev, A., Bassalat, A., Bates, R. L., Batista, S. J., Batley, J. R., Battaglia, M., Bauce, M., Bauer, F., Bawa, H. S., Beacham, J. B., Beattie, M. D., Beau, T., Beauchemin, P. H., Bechtle, P., Beck, H. P., Beck, H. C., Becker, K., Becker, M., Becot, C., Beddall, A. J., Beddall, A., Bednyakov, V. A., Bedognetti, M., Bee, C. P., Beermann, T. A., Begalli, M., Begel, M., Behr, J. K., Bell, A. S., Bella, G., Bellagamba, L., Bellerive, A., Bellomo, M., Belotskiy, K., Beltramello, O., Belyaev, N. L., Benary, O., Benchekroun, D., Bender, M., Benekos, N., Benhammou, Y., Benhar Noccioli, E., Benitez, J., Benjamin, D. P., Benoit, M., Bensinger, J. R., Bentvelsen, S., Beresford, L., Beretta, M., Berge, D., Bergeaas Kuutmann, E., Berger, N., Bergsten, L. J., Beringer, J., Berlendis, S., Bernard, N. R., Bernardi, G., Bernius, C., Bernlochner, F. U., Berry, T., Berta, P., Bertella, C., Bertoli, G., Bertram, I. A., Bertsche, C., Besjes, G. J., Bessidskaia Bylund, O., Bessner, M., Besson, N., Bethani, A., Bethke, S., Betti, A., Bevan, A. J., Beyer, J., Bianchi, R. M., Biebel, O., Biedermann, D., Bielski, R., Bierwagen, K., Biesuz, N. V., Biglietti, M., Billoud, T. R. V., Bilokon, H., Bindi, M., Bingul, A., Bini, C., Biondi, S., Bisanz, T., Bittrich, C., Bjergaard, D. M., Black, J. E., Black, K. M., Blair, R. E., Blazek, T., Bloch, I., Blocker, C., Blue, A., Blumenschein, U., Blunier, Dr., Bobbink, G. J., Bobrovnikov, V. S., Bocchetta, S. S., Bocci, A., Bock, C., Boehler, M., Boerner, D., Bogavac, D., Bogdanchikov, A. G., Bohm, C., Boisvert, V., Bokan, P., Bold, T., Boldyrev, A. S., Bolz, A. E., Bomben, M., Bona, M., Boonekamp, M., Borisov, A., Borissov, G., Bortfeldt, J., Bortoletto, D., Bortolotto, V., Boscherini, D., Bosman, M., Bossio Sola, J. D., Boudreau, J., Bouhova-Thacker, E. V., Boumediene, D., Bourdarios, C., Boutle, S. K., Boveia, A., Boyd, J., Boyko, I. R., Bozson, A. J., Bracinik, J., Brandt, A., Brandt, G., Brandt, O., Braren, F., Bratzler, U., Brau, B., Brau, J. E., Breaden Madden, W. D., Brendlinger, K., Brennan, A. J., Brenner, L., Brenner, R., Bressler, S., Briglin, D. L., Bristow, T. M., Britton, D., Britzger, D., Brochu, F. M., Brock, I., Brock, R., Brooijmans, G., Brooks, T., Brooks, W. K., Brosamer, J., Brost, E., Broughton, J. H., Bruckman de Renstrom, P. A., Bruncko, D., Bruni, A., Bruni, G., Bruni, L. S., Bruno, S., Brunt, B. H., Bruschi, M., Bruscino, N., Bryant, P., Bryngemark, L., Buanes, T., Buat, Q., Buchholz, P., Buckley, A. G., Budagov, I. A., Buehrer, F., Bugge, M. K., Bulekov, O., Bullock, D., Burch, T. J., Burdin, S., Burgard, C. D., Burger, A. M., Burghgrave, B., Burka, K., Burke, S., Burmeister, I., Burr, J. T. P., Büscher, D., Büscher, V., Bussey, P., Butler, J. M., Buttar, C. M., Butterworth, J. M., Butti, P., Buttinger, W., Buzatu, A., Buzykaev, A. R., Cabrera Urbán, S., Caforio, D., Cai, H., Cairo, V. M., Cakir, O., Calace, N., Calafiura, P., Calandri, A., Calderini, G., Calfayan, P., Callea, G., Caloba, L. P., Calvente Lopez, S., Calvet, D., Calvet, S., Calvet, T. P., Camacho Toro, R., Camarda, S., Camarri, P., Cameron, D., Caminal Armadans, R., Camincher, C., Campana, S., Campanelli, M., Camplani, A., Campoverde, A., Canale, V., Cano Bret, M., Cantero, J., Cao, T., Capeans Garrido, M. D. M., Caprini, I., Caprini, M., Capua, M., Carbone, R. M., Cardarelli, R., Cardillo, F., Carli, I., Carli, T., Carlino, G., Carlson, B. T., Carminati, L., Carney, R. M. D., Caron, S., Carquin, E., Carrá, S., Carrillo-Montoya, G. D., Casadei, D., Casado, M. P., Casha, A. F., Casolino, M., Casper, D. W., Castelijn, R., Castillo Gimenez, V., Castro, N. F., Catinaccio, A., Catmore, J. R., Cattai, A., Caudron, J., Cavaliere, V., Cavallaro, E., Cavalli, D., Cavalli-Sforza, M., Cavasinni, V., Celebi, E., Ceradini, F., Cerda Alberich, L., Cerqueira, A. S., Cerri, A., Cerrito, L., Cerutti, F., Cervelli, A., Cetin, S. A., Chafaq, A., Chakraborty, D., Chan, S. K., Chan, W. S., Chan, Y. L., Chang, P., Chapman, J. D., Charlton, D. G., Chau, C. C., Chavez Barajas, C. A., Che, S., Cheatham, S., Chegwidden, A., Chekanov, S., Chekulaev, S. V., Chelkov, G. A., Chelstowska, M. A., Chen, C., Chen, C., Chen, H., Chen, J., Chen, S., Chen, S., Chen, X., Chen, Y., Cheng, H. C., Cheng, H. J., Cheplakov, A., Cheremushkina, E., Cherkaoui El Moursli, R., Cheu, E., Cheung, K., Chevalier, L., Chiarella, V., Chiarelli, G., Chiodini, G., Chisholm, A. S., Chitan, A., Chiu, Y. H., Chizhov, M. V., Choi, K., Chomont, A. R., Chouridou, S., Chow, Y. S., Christodoulou, V., Chu, M. C., Chudoba, J., Chuinard, A. J., Chwastowski, J. J., Chytka, L., Ciftci, A. K., Cinca, D., Cindro, V., Cioară, I. A., Ciocio, A., Cirotto, F., Citron, Z. H., Citterio, M., Ciubancan, M., Clark, A., Clark, B. L., Clark, M. R., Clark, P. J., Clarke, R. N., Clement, C., Coadou, Y., Cobal, M., Coccaro, A., Cochran, J., Colasurdo, L., Cole, B., Colijn, A. P., Collot, J., Colombo, T., Conde Muiño, P., Coniavitis, E., Connell, S. H., Connelly, I. A., Constantinescu, S., Conti, G., Conventi, F., Cooke, M., Cooper-Sarkar, A. M., Cormier, F., Cormier, K. J. R., Corradi, M., Corriveau, F., Cortes-Gonzalez, A., Costa, G., Costa, M. J., Costanzo, D., Cottin, G., Cowan, G., Cox, B. E., Cranmer, K., Crawley, S. J., Creager, R. A., Cree, G., Crépé-Renaudin, S., Crescioli, F., Cribbs, W. A., Cristinziani, M., Croft, V., Crosetti, G., Cueto, A., Cuhadar Donszelmann, T., Cukierman, A. R., Cummings, J., Curatolo, M., Cúth, J., Czekierda, S., Czodrowski, P., D’amen, G., D’Auria, S., D’eramo, L., D’Onofrio, M., Da Cunha Sargedas De Sousa, M. J., Da Via, C., Dabrowski, W., Dado, T., Dai, T., Dale, O., Dallaire, F., Dallapiccola, C., Dam, M., Dandoy, J. R., Daneri, M. F., Dang, N. P., Daniells, A. C., Dann, N. S., Danninger, M., Dano Hoffmann, M., Dao, V., Darbo, G., Darmora, S., Dassoulas, J., Dattagupta, A., Daubney, T., Davey, W., David, C., Davidek, T., Davis, D. R., Davison, P., Dawe, E., Dawson, I., De, K., de Asmundis, R., De Benedetti, A., De Castro, S., De Cecco, S., De Groot, N., de Jong, P., De la Torre, H., De Lorenzi, F., De Maria, A., De Pedis, D., De Salvo, A., De Sanctis, U., De Santo, A., De Vasconcelos Corga, K., De Vivie De Regie, J. B., Debbe, R., Debenedetti, C., Dedovich, D. V., Dehghanian, N., Deigaard, I., Del Gaudio, M., Del Peso, J., Delgove, D., Deliot, F., Delitzsch, C. M., Dell’Acqua, A., Dell’Asta, L., Dell’Orso, M., Della Pietra, M., della Volpe, D., Delmastro, M., Delporte, C., Delsart, P. A., DeMarco, D. A., Demers, S., Demichev, M., Demilly, A., Denisov, S. P., Denysiuk, D., Derendarz, D., Derkaoui, J. E., Derue, F., Dervan, P., Desch, K., Deterre, C., Dette, K., Devesa, M. R., Deviveiros, P. O., Dewhurst, A., Dhaliwal, S., Di Bello, F. A., Di Ciaccio, A., Di Ciaccio, L., Di Clemente, W. K., Di Donato, C., Di Girolamo, A., Di Girolamo, B., Di Micco, B., Di Nardo, R., Di Petrillo, K. F., Di Simone, A., Di Sipio, R., Di Valentino, D., Diaconu, C., Diamond, M., Dias, F. A., Diaz, M. A., Dickinson, J., Diehl, E. B., Dietrich, J., Díez Cornell, S., Dimitrievska, A., Dingfelder, J., Dita, P., Dita, S., Dittus, F., Djama, F., Djobava, T., Djuvsland, J. I., do Vale, M. A. B., Dobos, D., Dobre, M., Dodsworth, D., Doglioni, C., Dolejsi, J., Dolezal, Z., Donadelli, M., Donati, S., Dondero, P., Donini, J., Dopke, J., Doria, A., Dova, M. T., Doyle, A. T., Drechsler, E., Dris, M., Du, Y., Duarte-Campderros, J., Dubinin, F., Dubreuil, A., Duchovni, E., Duckeck, G., Ducourthial, A., Ducu, O. A., Duda, D., Dudarev, A., Dudder, A. Chr., Duffield, E. M., Duflot, L., Dührssen, M., Dulsen, C., Dumancic, M., Dumitriu, A. E., Duncan, A. K., Dunford, M., Duperrin, A., Duran Yildiz, H., Düren, M., Durglishvili, A., Duschinger, D., Dutta, B., Duvnjak, D., Dyndal, M., Dziedzic, B. S., Eckardt, C., Ecker, K. M., Edgar, R. C., Eifert, T., Eigen, G., Einsweiler, K., Ekelof, T., El Kacimi, M., El Kosseifi, R., Ellajosyula, V., Ellert, M., Elles, S., Ellinghaus, F., Elliot, A. A., Ellis, N., Elmsheuser, J., Elsing, M., Emeliyanov, D., Enari, Y., Ennis, J. S., Epland, M. B., Erdmann, J., Ereditato, A., Ernst, M., Errede, S., Escalier, M., Escobar, C., Esposito, B., Estrada Pastor, O., Etienvre, A. I., Etzion, E., Evans, H., Ezhilov, A., Ezzi, M., Fabbri, F., Fabbri, L., Fabiani, V., Facini, G., Fakhrutdinov, R. M., Falciano, S., Falla, R. J., Faltova, J., Fang, Y., Fanti, M., Farbin, A., Farilla, A., Farina, C., Farina, E. M., Farooque, T., Farrell, S., Farrington, S. M., Farthouat, P., Fassi, F., Fassnacht, P., Fassouliotis, D., Faucci Giannelli, M., Favareto, A., Fawcett, W. J., Fayard, L., Fedin, O. L., Fedorko, W., Feigl, S., Feligioni, L., Feng, C., Feng, E. J., Fenton, M. J., Fenyuk, A. B., Feremenga, L., Fernandez Martinez, P., Ferrando, J., Ferrari, A., Ferrari, P., Ferrari, R., Ferreira de Lima, D. E., Ferrer, A., Ferrere, D., Ferretti, C., Fiedler, F., Filipčič, A., Filipuzzi, M., Filthaut, F., Fincke-Keeler, M., Finelli, K. D., Fiolhais, M. C. N., Fiorini, L., Fischer, A., Fischer, C., Fischer, J., Fisher, W. C., Flaschel, N., Fleck, I., Fleischmann, P., Fletcher, R. R. M., Flick, T., Flierl, B. M., Flores Castillo, L. R., Flowerdew, M. J., Forcolin, G. T., Formica, A., Förster, F. A., Forti, A., Foster, A. G., Fournier, D., Fox, H., Fracchia, S., Francavilla, P., Franchini, M., Franchino, S., Francis, D., Franconi, L., Franklin, M., Frate, M., Fraternali, M., Freeborn, D., Fressard-Batraneanu, S. M., Freund, B., Froidevaux, D., Frost, J. A., Fukunaga, C., Fusayasu, T., Fuster, J., Gabizon, O., Gabrielli, A., Gabrielli, A., Gach, G. P., Gadatsch, S., Gadomski, S., Gagliardi, G., Gagnon, L. G., Galea, C., Galhardo, B., Gallas, E. J., Gallop, B. J., Gallus, P., Galster, G., Gan, K. K., Ganguly, S., Gao, Y., Gao, Y. S., Garay Walls, F. M., García, C., García Navarro, J. E., García Pascual, J. A., Garcia-Sciveres, M., Gardner, R. W., Garelli, N., Garonne, V., Gascon Bravo, A., Gasnikova, K., Gatti, C., Gaudiello, A., Gaudio, G., Gavrilenko, I. L., Gay, C., Gaycken, G., Gazis, E. N., Gee, C. N. P., Geisen, J., Geisen, M., Geisler, M. P., Gellerstedt, K., Gemme, C., Genest, M. H., Geng, C., Gentile, S., Gentsos, C., George, S., Gerbaudo, D., Geßner, G., Ghasemi, S., Ghneimat, M., Giacobbe, B., Giagu, S., Giangiacomi, N., Giannetti, P., Gibson, S. M., Gignac, M., Gilchriese, M., Gillberg, D., Gilles, G., Gingrich, D. M., Giordani, M. P., Giorgi, F. M., Giraud, P. F., Giromini, P., Giugliarelli, G., Giugni, D., Giuli, F., Giuliani, C., Giulini, M., Gjelsten, B. K., Gkaitatzis, S., Gkialas, I., Gkougkousis, E. L., Gkountoumis, P., Gladilin, L. K., Glasman, C., Glatzer, J., Glaysher, P. C. F., Glazov, A., Goblirsch-Kolb, M., Godlewski, J., Goldfarb, S., Golling, T., Golubkov, D., Gomes, A., Gonçalo, R., Goncalves Gama, R., Goncalves Pinto Firmino Da Costa, J., Gonella, G., Gonella, L., Gongadze, A., Gonski, J. L., González de la Hoz, S., Gonzalez-Sevilla, S., Goossens, L., Gorbounov, P. A., Gordon, H. A., Gorelov, I., Gorini, B., Gorini, E., Gorišek, A., Goshaw, A. T., Gössling, C., Gostkin, M. I., Gottardo, C. A., Goudet, C. R., Goujdami, D., Goussiou, A. G., Govender, N., Gozani, E., Grabowska-Bold, I., Gradin, P. O. J., Gramling, J., Gramstad, E., Grancagnolo, S., Gratchev, V., Gravila, P. M., Gray, C., Gray, H. M., Greenwood, Z. D., Grefe, C., Gregersen, K., Gregor, I. M., Grenier, P., Grevtsov, K., Griffiths, J., Grillo, A. A., Grimm, K., Grinstein, S., Gris, Ph., Grivaz, J.-F., Groh, S., Gross, E., Grosse-Knetter, J., Grossi, G. C., Grout, Z. J., Grummer, A., Guan, L., Guan, W., Guenther, J., Guescini, F., Guest, D., Gueta, O., Gui, B., Guido, E., Guillemin, T., Guindon, S., Gul, U., Gumpert, C., Guo, J., Guo, W., Guo, Y., Gupta, R., Gurbuz, S., Gustavino, G., Gutelman, B. J., Gutierrez, P., Gutierrez Ortiz, N. G., Gutschow, C., Guyot, C., Guzik, M. P., Gwenlan, C., Gwilliam, C. B., Haas, A., Haber, C., Hadavand, H. K., Haddad, N., Hadef, A., Hageböck, S., Hagihara, M., Hakobyan, H., Haleem, M., Haley, J., Halladjian, G., Hallewell, G. D., Hamacher, K., Hamal, P., Hamano, K., Hamilton, A., Hamity, G. N., Hamnett, P. G., Han, L., Han, S., Hanagaki, K., Hanawa, K., Hance, M., Handl, D. M., Haney, B., Hanke, P., Hansen, J. B., Hansen, J. D., Hansen, M. C., Hansen, P. H., Hara, K., Hard, A. S., Harenberg, T., Hariri, F., Harkusha, S., Harrison, P. F., Hartmann, N. M., Hasegawa, Y., Hasib, A., Hassani, S., Haug, S., Hauser, R., Hauswald, L., Havener, L. B., Havranek, M., Hawkes, C. M., Hawkings, R. J., Hayakawa, D., Hayden, D., Hays, C. P., Hays, J. M., Hayward, H. S., Haywood, S. J., Head, S. J., Heck, T., Hedberg, V., Heelan, L., Heer, S., Heidegger, K. K., Heim, S., Heim, T., Heinemann, B., Heinrich, J. J., Heinrich, L., Heinz, C., Hejbal, J., Helary, L., Held, A., Hellman, S., Helsens, C., Henderson, R. C. W., Heng, Y., Henkelmann, S., Henriques Correia, A. M., Henrot-Versille, S., Herbert, G. H., Herde, H., Herget, V., Hernández Jiménez, Y., Herr, H., Herten, G., Hertenberger, R., Hervas, L., Herwig, T. C., Hesketh, G. G., Hessey, N. P., Hetherly, J. W., Higashino, S., Higón-Rodriguez, E., Hildebrand, K., Hill, E., Hill, J. C., Hiller, K. H., Hillier, S. J., Hils, M., Hinchliffe, I., Hirose, M., Hirschbuehl, D., Hiti, B., Hladik, O., Hlaluku, D. R., Hoad, X., Hobbs, J., Hod, N., Hodgkinson, M. C., Hodgson, P., Hoecker, A., Hoeferkamp, M. R., Hoenig, F., Hohn, D., Holmes, T. R., Holzbock, M., Homann, M., Honda, S., Honda, T., Hong, T. M., Hooberman, B. H., Hopkins, W. H., Horii, Y., Horton, A. J., Hostachy, J-Y., Hostiuc, A., Hou, S., Hoummada, A., Howarth, J., Hoya, J., Hrabovsky, M., Hrdinka, J., Hristova, I., Hrivnac, J., Hryn’ova, T., Hrynevich, A., Hsu, P. J., Hsu, S.-C., Hu, Q., Hu, S., Huang, Y., Hubacek, Z., Hubaut, F., Huegging, F., Huffman, T. B., Hughes, E. W., Huhtinen, M., Hunter, R. F. H., Huo, P., Huseynov, N., Huston, J., Huth, J., Hyneman, R., Iacobucci, G., Iakovidis, G., Ibragimov, I., Iconomidou-Fayard, L., Idrissi, Z., Iengo, P., Igonkina, O., Iizawa, T., Ikegami, Y., Ikeno, M., Ilchenko, Y., Iliadis, D., Ilic, N., Iltzsche, F., Introzzi, G., Ioannou, P., Iodice, M., Iordanidou, K., Ippolito, V., Isacson, M. F., Ishijima, N., Ishino, M., Ishitsuka, M., Issever, C., Istin, S., Ito, F., Iturbe Ponce, J. M., Iuppa, R., Iwasaki, H., Izen, J. M., Izzo, V., Jabbar, S., Jackson, P., Jacobs, R. M., Jain, V., Jakobi, K. B., Jakobs, K., Jakobsen, S., Jakoubek, T., Jamin, D. O., Jana, D. K., Jansky, R., Janssen, J., Janus, M., Janus, P. A., Jarlskog, G., Javadov, N., Javůrek, T., Javurkova, M., Jeanneau, F., Jeanty, L., Jejelava, J., Jelinskas, A., Jenni, P., Jeske, C., Jézéquel, S., Ji, H., Jia, J., Jiang, H., Jiang, Y., Jiang, Z., Jiggins, S., Jimenez Pena, J., Jin, S., Jinaru, A., Jinnouchi, O., Jivan, H., Johansson, P., Johns, K. A., Johnson, C. A., Johnson, W. J., Jon-And, K., Jones, R. W. L., Jones, S. D., Jones, S., Jones, T. J., Jongmanns, J., Jorge, P. M., Jovicevic, J., Ju, X., Juste Rozas, A., Köhler, M. K., Kaczmarska, A., Kado, M., Kagan, H., Kagan, M., Kahn, S. J., Kaji, T., Kajomovitz, E., Kalderon, C. W., Kaluza, A., Kama, S., Kamenshchikov, A., Kanaya, N., Kanjir, L., Kantserov, V. A., Kanzaki, J., Kaplan, B., Kaplan, L. S., Kar, D., Karakostas, K., Karastathis, N., Kareem, M. J., Karentzos, E., Karpov, S. N., Karpova, Z. M., Karthik, K., Kartvelishvili, V., Karyukhin, A. N., Kasahara, K., Kashif, L., Kass, R. D., Kastanas, A., Kataoka, Y., Kato, C., Katre, A., Katzy, J., Kawade, K., Kawagoe, K., Kawamoto, T., Kawamura, G., Kay, E. F., Kazanin, V. F., Keeler, R., Kehoe, R., Keller, J. S., Kellermann, E., Kempster, J. J., Kendrick, J., Keoshkerian, H., Kepka, O., Kerševan, B. P., Kersten, S., Keyes, R. A., Khader, M., Khalil-zada, F., Khanov, A., Kharlamov, A. G., Kharlamova, T., Khodinov, A., Khoo, T. J., Khovanskiy, V., Khramov, E., Khubua, J., Kido, S., Kilby, C. R., Kim, H. Y., Kim, S. H., Kim, Y. K., Kimura, N., Kind, O. M., King, B. T., Kirchmeier, D., Kirk, J., Kiryunin, A. E., Kishimoto, T., Kisielewska, D., Kitali, V., Kivernyk, O., Kladiva, E., Klapdor-Kleingrothaus, T., Klein, M. H., Klein, M., Klein, U., Kleinknecht, K., Klimek, P., Klimentov, A., Klingenberg, R., Klingl, T., Klioutchnikova, T., Klitzner, F. F., Kluge, E.-E., Kluit, P., Kluth, S., Kneringer, E., Knoops, E. B. F. G., Knue, A., Kobayashi, A., Kobayashi, D., Kobayashi, T., Kobel, M., Kocian, M., Kodys, P., Koffas, T., Koffeman, E., Köhler, N. M., Koi, T., Kolb, M., Koletsou, I., Kondo, T., Kondrashova, N., Köneke, K., König, A. C., Kono, T., Konoplich, R., Konstantinidis, N., Konya, B., Kopeliansky, R., Koperny, S., Kopp, A. K., Korcyl, K., Kordas, K., Korn, A., Korol, A. A., Korolkov, I., Korolkova, E. V., Kortner, O., Kortner, S., Kosek, T., Kostyukhin, V. V., Kotwal, A., Koulouris, A., Kourkoumeli-Charalampidi, A., Kourkoumelis, C., Kourlitis, E., Kouskoura, V., Kowalewska, A. B., Kowalewski, R., Kowalski, T. Z., Kozakai, C., Kozanecki, W., Kozhin, A. S., Kramarenko, V. A., Kramberger, G., Krasnopevtsev, D., Krasny, M. W., Krasznahorkay, A., Krauss, D., Kremer, J. A., Kretzschmar, J., Kreutzfeldt, K., Krieger, P., Krizka, K., Kroeninger, K., Kroha, H., Kroll, J., Kroll, J., Kroseberg, J., Krstic, J., Kruchonak, U., Krüger, H., Krumnack, N., Kruse, M. C., Kubota, T., Kucuk, H., Kuday, S., Kuechler, J. T., Kuehn, S., Kugel, A., Kuger, F., Kuhl, T., Kukhtin, V., Kukla, R., Kulchitsky, Y., Kuleshov, S., Kulinich, Y. P., Kuna, M., Kunigo, T., Kupco, A., Kupfer, T., Kuprash, O., Kurashige, H., Kurchaninov, L. L., Kurochkin, Y. A., Kurth, M. G., Kuwertz, E. S., Kuze, M., Kvita, J., Kwan, T., Kyriazopoulos, D., La Rosa, A., La Rosa Navarro, J. L., La Rotonda, L., La Ruffa, F., Lacasta, C., Lacava, F., Lacey, J., Lack, D. P. J., Lacker, H., Lacour, D., Ladygin, E., Lafaye, R., Laforge, B., Lai, S., Lammers, S., Lampl, W., Lançon, E., Landgraf, U., Landon, M. P. J., Lanfermann, M. C., Lang, V. S., Lange, J. C., Langenberg, R. J., Lankford, A. J., Lanni, F., Lantzsch, K., Lanza, A., Lapertosa, A., Laplace, S., Laporte, J. F., Lari, T., Lasagni Manghi, F., Lassnig, M., Lau, T. S., Laurelli, P., Lavrijsen, W., Law, A. T., Laycock, P., Lazovich, T., Lazzaroni, M., Le, B., Le Dortz, O., Le Guirriec, E., Le Quilleuc, E. P., LeBlanc, M., LeCompte, T., Ledroit-Guillon, F., Lee, C. A., Lee, G. R., Lee, S. C., Lee, L., Lefebvre, B., Lefebvre, G., Lefebvre, M., Legger, F., Leggett, C., Lehmann Miotto, G., Lei, X., Leight, W. A., Leite, M. A. L., Leitner, R., Lellouch, D., Lemmer, B., Leney, K. J. C., Lenz, T., Lenzi, B., Leone, R., Leone, S., Leonidopoulos, C., Lerner, G., Leroy, C., Les, R., Lesage, A. A. J., Lester, C. G., Levchenko, M., Levêque, J., Levin, D., Levinson, L. J., Levy, M., Lewis, D., Li, B., Li, C.-Q., Li, H., Li, L., Li, Q., Li, Q., Li, S., Li, X., Li, Y., Liang, Z., Liberti, B., Liblong, A., Lie, K., Liebal, J., Liebig, W., Limosani, A., Lin, C. Y., Lin, K., Lin, S. C., Lin, T. H., Linck, R. A., Lindquist, B. E., Lionti, A. E., Lipeles, E., Lipniacka, A., Lisovyi, M., Liss, T. M., Lister, A., Litke, A. M., Liu, B., Liu, H., Liu, H., Liu, J. K. K., Liu, J., Liu, J. B., Liu, K., Liu, L., Liu, M., Liu, Y. L., Liu, Y., Livan, M., Lleres, A., Llorente Merino, J., Lloyd, S. L., Lo, C. Y., Lo Sterzo, F., Lobodzinska, E. M., Loch, P., Loebinger, F. K., Loesle, A., Loew, K. M., Lohse, T., Lohwasser, K., Lokajicek, M., Long, B. A., Long, J. D., Long, R. E., Longo, L., Looper, K. A., Lopez, J. A., Lopez Paz, I., Lopez Solis, A., Lorenz, J., Lorenzo Martinez, N., Losada, M., Lösel, P. J., Lou, X., Lounis, A., Love, J., Love, P. A., Lu, H., Lu, N., Lu, Y. J., Lubatti, H. J., Luci, C., Lucotte, A., Luedtke, C., Luehring, F., Lukas, W., Luminari, L., Lundberg, O., Lund-Jensen, B., Lutz, M. S., Luzi, P. M., Lynn, D., Lysak, R., Lytken, E., Lyu, F., Lyubushkin, V., Ma, H., Ma, L. L., Ma, Y., Maccarrone, G., Macchiolo, A., Macdonald, C. M., Maček, B., Machado Miguens, J., Madaffari, D., Madar, R., Mader, W. F., Madsen, A., Madysa, N., Maeda, J., Maeland, S., Maeno, T., Maevskiy, A. S., Magerl, V., Maiani, C., Maidantchik, C., Maier, T., Maio, A., Majersky, O., Majewski, S., Makida, Y., Makovec, N., Malaescu, B., Malecki, Pa., Maleev, V. P., Malek, F., Mallik, U., Malon, D., Malone, C., Maltezos, S., Malyukov, S., Mamuzic, J., Mancini, G., Mandić, I., Maneira, J., Manhaes de Andrade Filho, L., Manjarres Ramos, J., Mankinen, K. H., Mann, A., Manousos, A., Mansoulie, B., Mansour, J. D., Mantifel, R., Mantoani, M., Manzoni, S., Mapelli, L., Marceca, G., March, L., Marchese, L., Marchiori, G., Marcisovsky, M., Marin Tobon, C. A., Marjanovic, M., Marley, D. E., Marroquim, F., Marsden, S. P., Marshall, Z., Martensson, M. U. F., Marti-Garcia, S., Martin, C. B., Martin, T. A., Martin, V. J., Martin dit Latour, B., Martinez, M., Martinez Outschoorn, V. I., Martin-Haugh, S., Martoiu, V. S., Martyniuk, A. C., Marzin, A., Masetti, L., Mashimo, T., Mashinistov, R., Masik, J., Maslennikov, A. L., Mason, L. H., Massa, L., Mastrandrea, P., Mastroberardino, A., Masubuchi, T., Mättig, P., Maurer, J., Maxfield, S. J., Maximov, D. A., Mazini, R., Maznas, I., Mazza, S. M., Mc Fadden, N. C., Mc Goldrick, G., Mc Kee, S. P., McCarn, A., McCarthy, R. L., McCarthy, T. G., McClymont, L. I., McDonald, E. F., Mcfayden, J. A., Mchedlidze, G., McMahon, S. J., McNamara, P. C., McNicol, C. J., McPherson, R. A., Meehan, S., Megy, T. J., Mehlhase, S., Mehta, A., Meideck, T., Meier, K., Meirose, B., Melini, D., Mellado Garcia, B. R., Mellenthin, J. D., Melo, M., Meloni, F., Melzer, A., Menary, S. B., Meng, L., Meng, X. T., Mengarelli, A., Menke, S., Meoni, E., Mergelmeyer, S., Merlassino, C., Mermod, P., Merola, L., Meroni, C., Merritt, F. S., Messina, A., Metcalfe, J., Mete, A. S., Meyer, C., Meyer, J-P., Meyer, J., Meyer Zu Theenhausen, H., Miano, F., Middleton, R. P., Miglioranzi, S., Mijović, L., Mikenberg, G., Mikestikova, M., Mikuž, M., Milesi, M., Milic, A., Millar, D. A., Miller, D. W., Mills, C., Milov, A., Milstead, D. A., Minaenko, A. A., Minami, Y., Minashvili, I. A., Mincer, A. I., Mindur, B., Mineev, M., Minegishi, Y., Ming, Y., Mir, L. M., Mirto, A., Mistry, K. P., Mitani, T., Mitrevski, J., Mitsou, V. A., Miucci, A., Miyagawa, P. S., Mizukami, A., Mjörnmark, J. U., Mkrtchyan, T., Mlynarikova, M., Moa, T., Mochizuki, K., Mogg, P., Mohapatra, S., Molander, S., Moles-Valls, R., Mondragon, M. C., Mönig, K., Monk, J., Monnier, E., Montalbano, A., Montejo Berlingen, J., Monticelli, F., Monzani, S., Moore, R. W., Morange, N., Moreno, D., Moreno Llácer, M., Morettini, P., Morgenstern, S., Mori, D., Mori, T., Morii, M., Morinaga, M., Morisbak, V., Morley, A. K., Mornacchi, G., Morris, J. D., Morvaj, L., Moschovakos, P., Mosidze, M., Moss, H. J., Moss, J., Motohashi, K., Mount, R., Mountricha, E., Moyse, E. J. W., Muanza, S., Mueller, F., Mueller, J., Mueller, R. S. P., Muenstermann, D., Mullen, P., Mullier, G. A., Munoz Sanchez, F. J., Murray, W. J., Musheghyan, H., Muškinja, M., Myagkov, A. G., Myska, M., Nachman, B. P., Nackenhorst, O., Nagai, K., Nagai, R., Nagano, K., Nagasaka, Y., Nagata, K., Nagel, M., Nagy, E., Nairz, A. M., Nakahama, Y., Nakamura, K., Nakamura, T., Nakano, I., Naranjo Garcia, R. F., Narayan, R., Narrias Villar, D. I., Naryshkin, I., Naumann, T., Navarro, G., Nayyar, R., Neal, H. A., Nechaeva, P. Yu., Neep, T. J., Negri, A., Negrini, M., Nektarijevic, S., Nellist, C., Nelson, A., Nelson, M. E., Nemecek, S., Nemethy, P., Nessi, M., Neubauer, M. S., Neumann, M., Newman, P. R., Ng, T. Y., Ng, Y. S., Nguyen Manh, T., Nickerson, R. B., Nicolaidou, R., Nielsen, J., Nikiforou, N., Nikolaenko, V., Nikolic-Audit, I., Nikolopoulos, K., Nilsson, P., Ninomiya, Y., Nisati, A., Nishu, N., Nisius, R., Nitsche, I., Nitta, T., Nobe, T., Noguchi, Y., Nomachi, M., Nomidis, I., Nomura, M. A., Nooney, T., Nordberg, M., Norjoharuddeen, N., Novgorodova, O., Nozaki, M., Nozka, L., Ntekas, K., Nurse, E., Nuti, F., O’connor, K., O’Neil, D. C., O’Rourke, A. A., O’Shea, V., Oakham, F. G., Oberlack, H., Obermann, T., Ocariz, J., Ochi, A., Ochoa, I., Ochoa-Ricoux, J. P., Oda, S., Odaka, S., Oh, A., Oh, S. H., Ohm, C. C., Ohman, H., Oide, H., Okawa, H., Okumura, Y., Okuyama, T., Olariu, A., Oleiro Seabra, L. F., Olivares Pino, S. A., Oliveira Damazio, D., Olsson, M. J. R., Olszewski, A., Olszowska, J., Onofre, A., Onogi, K., Onyisi, P. U. E., Oppen, H., Oreglia, M. J., Oren, Y., Orestano, D., Orlando, N., Orr, R. S., Osculati, B., Ospanov, R., Otero y Garzon, G., Otono, H., Ouchrif, M., Ould-Saada, F., Ouraou, A., Oussoren, K. P., Ouyang, Q., Owen, M., Owen, R. E., Ozcan, V. E., Ozturk, N., Pachal, K., Pacheco Pages, A., Pacheco Rodriguez, L., Padilla Aranda, C., Pagan Griso, S., Paganini, M., Paige, F., Palacino, G., Palazzo, S., Palestini, S., Palka, M., Pallin, D., St. Panagiotopoulou, E., Panagoulias, I., Pandini, C. E., Panduro Vazquez, J. G., Pani, P., Panitkin, S., Pantea, D., Paolozzi, L., Papadopoulou, Th. D., Papageorgiou, K., Paramonov, A., Paredes Hernandez, D., Parker, A. J., Parker, M. A., Parker, K. A., Parodi, F., Parsons, J. A., Parzefall, U., Pascuzzi, V. R., Pasner, J. M., Pasqualucci, E., Passaggio, S., Pastore, Fr., Pataraia, S., Pater, J. R., Pauly, T., Pearson, B., Pedraza Lopez, S., Pedro, R., Peleganchuk, S. V., Penc, O., Peng, C., Peng, H., Penwell, J., Peralva, B. S., Perego, M. M., Perepelitsa, D. V., Peri, F., Perini, L., Pernegger, H., Perrella, S., Peschke, R., Peshekhonov, V. D., Peters, K., Peters, R. F. Y., Petersen, B. A., Petersen, T. C., Petit, E., Petridis, A., Petridou, C., Petroff, P., Petrolo, E., Petrov, M., Petrucci, F., Pettersson, N. E., Peyaud, A., Pezoa, R., Phillips, F. H., Phillips, P. W., Piacquadio, G., Pianori, E., Picazio, A., Pickering, M. A., Piegaia, R., Pilcher, J. E., Pilkington, A. D., Pinamonti, M., Pinfold, J. L., Pirumov, H., Pitt, M., Plazak, L., Pleier, M.-A., Pleskot, V., Plotnikova, E., Pluth, D., Podberezko, P., Poettgen, R., Poggi, R., Poggioli, L., Pogrebnyak, I., Pohl, D., Pokharel, I., Polesello, G., Poley, A., Policicchio, A., Polifka, R., Polini, A., Pollard, C. S., Polychronakos, V., Pommès, K., Ponomarenko, D., Pontecorvo, L., Popeneciu, G. A., Portillo Quintero, D. M., Pospisil, S., Potamianos, K., Potrap, I. N., Potter, C. J., Potti, H., Poulsen, T., Poveda, J., Pozo Astigarraga, M. E., Pralavorio, P., Pranko, A., Prell, S., Price, D., Primavera, M., Prince, S., Proklova, N., Prokofiev, K., Prokoshin, F., Protopopescu, S., Proudfoot, J., Przybycien, M., Puri, A., Puzo, P., Qian, J., Qin, G., Qin, Y., Quadt, A., Queitsch-Maitland, M., Quilty, D., Raddum, S., Radeka, V., Radescu, V., Radhakrishnan, S. K., Radloff, P., Rados, P., Ragusa, F., Rahal, G., Raine, J. A., Rajagopalan, S., Rangel-Smith, C., Rashid, T., Raspopov, S., Ratti, M. G., Rauch, D. M., Rauscher, F., Rave, S., Ravinovich, I., Rawling, J. H., Raymond, M., Read, A. L., Readioff, N. P., Reale, M., Rebuzzi, D. M., Redelbach, A., Redlinger, G., Reece, R., Reed, R. G., Reeves, K., Rehnisch, L., Reichert, J., Reiss, A., Rembser, C., Ren, H., Rescigno, M., Resconi, S., Resseguie, E. D., Rettie, S., Reynolds, E., Rezanova, O. L., Reznicek, P., Rezvani, R., Richter, R., Richter, S., Richter-Was, E., Ricken, O., Ridel, M., Rieck, P., Riegel, C. J., Rieger, J., Rifki, O., Rijssenbeek, M., Rimoldi, A., Rimoldi, M., Rinaldi, L., Ripellino, G., Ristić, B., Ritsch, E., Riu, I., Rizatdinova, F., Rizvi, E., Rizzi, C., Roberts, R. T., Robertson, S. H., Robichaud-Veronneau, A., Robinson, D., Robinson, J. E. M., Robson, A., Rocco, E., Roda, C., Rodina, Y., Rodriguez Bosca, S., Rodriguez Perez, A., Rodriguez Rodriguez, D., Roe, S., Rogan, C. S., Røhne, O., Roloff, J., Romaniouk, A., Romano, M., Romano Saez, S. M., Romero Adam, E., Rompotis, N., Ronzani, M., Roos, L., Rosati, S., Rosbach, K., Rose, P., Rosien, N.-A., Rossi, E., Rossi, L. P., Rosten, J. H. N., Rosten, R., Rotaru, M., Rothberg, J., Rousseau, D., Roy, D., Rozanov, A., Rozen, Y., Ruan, X., Rubbo, F., Rühr, F., Ruiz-Martinez, A., Rurikova, Z., Rusakovich, N. A., Russell, H. L., Rutherfoord, J. P., Ruthmann, N., Rüttinger, E. M., Ryabov, Y. F., Rybar, M., Rybkin, G., Ryu, S., Ryzhov, A., Rzehorz, G. F., Saavedra, A. F., Sabato, G., Sacerdoti, S., Sadrozinski, H. F-W., Sadykov, R., Safai Tehrani, F., Saha, P., Sahinsoy, M., Saimpert, M., Saito, M., Saito, T., Sakamoto, H., Sakurai, Y., Salamanna, G., Salazar Loyola, J. E., Salek, D., Sales De Bruin, P. H., Salihagic, D., Salnikov, A., Salt, J., Salvatore, D., Salvatore, F., Salvucci, A., Salzburger, A., Sammel, D., Sampsonidis, D., Sampsonidou, D., Sánchez, J., Sanchez Martinez, V., Sanchez Pineda, A., Sandaker, H., Sandbach, R. L., Sander, C. O., Sandhoff, M., Sandoval, C., Sankey, D. P. C., Sannino, M., Sano, Y., Sansoni, A., Santoni, C., Santos, H., Santoyo Castillo, I., Sapronov, A., Saraiva, J. G., Sarrazin, B., Sasaki, O., Sato, K., Sauvan, E., Savage, G., Savard, P., Savic, N., Sawyer, C., Sawyer, L., Saxon, J., Sbarra, C., Sbrizzi, A., Scanlon, T., Scannicchio, D. A., Schaarschmidt, J., Schacht, P., Schachtner, B. M., Schaefer, D., Schaefer, L., Schaefer, R., Schaeffer, J., Schaepe, S., Schaetzel, S., Schäfer, U., Schaffer, A. C., Schaile, D., Schamberger, R. D., Schegelsky, V. A., Scheirich, D., Schenck, F., Schernau, M., Schiavi, C., Schier, S., Schildgen, L. K., Schillo, C., Schioppa, M., Schlenker, S., Schmidt-Sommerfeld, K. R., Schmieden, K., Schmitt, C., Schmitt, S., Schmitz, S., Schnoor, U., Schoeffel, L., Schoening, A., Schoenrock, B. D., Schopf, E., Schott, M., Schouwenberg, J. F. P., Schovancova, J., Schramm, S., Schuh, N., Schulte, A., Schultens, M. J., Schultz-Coulon, H.-C., Schulz, H., Schumacher, M., Schumm, B. A., Schune, Ph., Schwartzman, A., Schwarz, T. A., Schweiger, H., Schwemling, Ph., Schwienhorst, R., Schwindling, J., Sciandra, A., Sciolla, G., Scornajenghi, M., Scuri, F., Scutti, F., Searcy, J., Seema, P., Seidel, S. C., Seiden, A., Seixas, J. M., Sekhniaidze, G., Sekhon, K., Sekula, S. J., Semprini-Cesari, N., Senkin, S., Serfon, C., Serin, L., Serkin, L., Sessa, M., Seuster, R., Severini, H., Šfiligoj, T., Sforza, F., Sfyrla, A., Shabalina, E., Shaikh, N. W., Shan, L. Y., Shang, R., Shank, J. T., Shapiro, M., Shatalov, P. B., Shaw, K., Shaw, S. M., Shcherbakova, A., Shehu, C. Y., Shen, Y., Sherafati, N., Sherman, A. D., Sherwood, P., Shi, L., Shimizu, S., Shimmin, C. O., Shimojima, M., Shipsey, I. P. J., Shirabe, S., Shiyakova, M., Shlomi, J., Shmeleva, A., Shoaleh Saadi, D., Shochet, M. J., Shojaii, S., Shope, D. R., Shrestha, S., Shulga, E., Shupe, M. A., Sicho, P., Sickles, A. M., Sidebo, P. E., Sideras Haddad, E., Sidiropoulou, O., Sidoti, A., Siegert, F., Sijacki, Dj., Silva, J., Silverstein, S. B., Simak, V., Simic, L., Simion, S., Simioni, E., Simmons, B., Simon, M., Sinervo, P., Sinev, N. B., Sioli, M., Siragusa, G., Siral, I., Sivoklokov, S. Yu., Sjölin, J., Skinner, M. B., Skubic, P., Slater, M., Slavicek, T., Slawinska, M., Sliwa, K., Slovak, R., Smakhtin, V., Smart, B. H., Smiesko, J., Smirnov, N., Smirnov, S. Yu., Smirnov, Y., Smirnova, L. N., Smirnova, O., Smith, J. W., Smith, M. N. K., Smith, R. W., Smizanska, M., Smolek, K., Snesarev, A. A., Snyder, I. M., Snyder, S., Sobie, R., Socher, F., Soffer, A., Søgaard, A., Soh, D. A., Sokhrannyi, G., Solans Sanchez, C. A., Solar, M., Soldatov, E. Yu., Soldevila, U., Solodkov, A. A., Soloshenko, A., Solovyanov, O. V., Solovyev, V., Sommer, P., Son, H., Sopczak, A., Sosa, D., Sotiropoulou, C. L., Sottocornola, S., Soualah, R., Soukharev, A. M., South, D., Sowden, B. C., Spagnolo, S., Spalla, M., Spangenberg, M., Spanò, F., Sperlich, D., Spettel, F., Spieker, T. M., Spighi, R., Spigo, G., Spiller, L. A., Spousta, M., St. Denis, R. D., Stabile, A., Stamen, R., Stamm, S., Stanecka, E., Stanek, R. W., Stanescu, C., Stanitzki, M. M., Stapf, B. S., Stapnes, S., Starchenko, E. A., Stark, G. H., Stark, J., Stark, S. H., Staroba, P., Starovoitov, P., Stärz, S., Staszewski, R., Stegler, M., Steinberg, P., Stelzer, B., Stelzer, H. J., Stelzer-Chilton, O., Stenzel, H., Stevenson, T. J., Stewart, G. A., Stockton, M. C., Stoebe, M., Stoicea, G., Stolte, P., Stonjek, S., Stradling, A. R., Straessner, A., Stramaglia, M. E., Strandberg, J., Strandberg, S., Strauss, M., Strizenec, P., Ströhmer, R., Strom, D. M., Stroynowski, R., Strubig, A., Stucci, S. A., Stugu, B., Styles, N. A., Su, D., Su, J., Suchek, S., Sugaya, Y., Suk, M., Sulin, V. V., Sultan, D. M. S., Sultansoy, S., Sumida, T., Sun, S., Sun, X., Suruliz, K., Suster, C. J. E., Sutton, M. R., Suzuki, S., Svatos, M., Swiatlowski, M., Swift, S. P., Sykora, I., Sykora, T., Ta, D., Tackmann, K., Taenzer, J., Taffard, A., Tafirout, R., Tahirovic, E., Taiblum, N., Takai, H., Takashima, R., Takasugi, E. H., Takeda, K., Takeshita, T., Takubo, Y., Talby, M., Talyshev, A. A., Tanaka, J., Tanaka, M., Tanaka, R., Tanaka, S., Tanioka, R., Tannenwald, B. B., Tapia Araya, S., Tapprogge, S., Tarem, S., Tartarelli, G. F., Tas, P., Tasevsky, M., Tashiro, T., Tassi, E., Tavares Delgado, A., Tayalati, Y., Taylor, A. C., Taylor, A. J., Taylor, G. N., Taylor, P. T. E., Taylor, W., Teixeira-Dias, P., Temple, D., Ten Kate, H., Teng, P. K., Teoh, J. J., Tepel, F., Terada, S., Terashi, K., Terron, J., Terzo, S., Testa, M., Teuscher, R. J., Thais, S. J., Theveneaux-Pelzer, T., Thiele, F., Thomas, J. P., Thomas-Wilsker, J., Thompson, P. D., Thompson, A. S., Thomsen, L. A., Thomson, E., Tian, Y., Tibbetts, M. J., Ticse Torres, R. E., Tikhomirov, V. O., Tikhonov, Yu. A., Timoshenko, S., Tipton, P., Tisserant, S., Todome, K., Todorova-Nova, S., Todt, S., Tojo, J., Tokár, S., Tokushuku, K., Tolley, E., Tomlinson, L., Tomoto, M., Tompkins, L., Toms, K., Tong, B., Tornambe, P., Torrence, E., Torres, H., Torró Pastor, E., Toth, J., Touchard, F., Tovey, D. R., Treado, C. J., Trefzger, T., Tresoldi, F., Tricoli, A., Trigger, I. M., Trincaz-Duvoid, S., Tripiana, M. F., Trischuk, W., Trocmé, B., Trofymov, A., Troncon, C., Trottier-McDonald, M., Trovatelli, M., Truong, L., Trzebinski, M., Trzupek, A., Tsang, K. W., Tseng, J. C-L., Tsiareshka, P. V., Tsirintanis, N., Tsiskaridze, S., Tsiskaridze, V., Tskhadadze, E. G., Tsukerman, I. I., Tsulaia, V., Tsuno, S., Tsybychev, D., Tu, Y., Tudorache, A., Tudorache, V., Tulbure, T. T., Tuna, A. N., Turchikhin, S., Turgeman, D., Turk Cakir, I., Turra, R., Tuts, P. M., Ucchielli, G., Ueda, I., Ughetto, M., Ukegawa, F., Unal, G., Undrus, A., Unel, G., Ungaro, F. C., Unno, Y., Uno, K., Unverdorben, C., Urban, J., Urquijo, P., Urrejola, P., Usai, G., Usui, J., Vacavant, L., Vacek, V., Vachon, B., Vadla, K. O. H., Vaidya, A., Valderanis, C., Valdes Santurio, E., Valente, M., Valentinetti, S., Valero, A., Valéry, L., Valkar, S., Vallier, A., Valls Ferrer, J. A., Van Den Wollenberg, W., van der Graaf, H., van Gemmeren, P., Van Nieuwkoop, J., van Vulpen, I., van Woerden, M. C., Vanadia, M., Vandelli, W., Vaniachine, A., Vankov, P., Vardanyan, G., Vari, R., Varnes, E. W., Varni, C., Varol, T., Varouchas, D., Vartapetian, A., Varvell, K. E., Vasquez, J. G., Vasquez, G. A., Vazeille, F., Vazquez Furelos, D., Vazquez Schroeder, T., Veatch, J., Veeraraghavan, V., Veloce, L. M., Veloso, F., Veneziano, S., Ventura, A., Venturi, M., Venturi, N., Venturini, A., Vercesi, V., Verducci, M., Verkerke, W., Vermeulen, A. T., Vermeulen, J. C., Vetterli, M. C., Viaux Maira, N., Viazlo, O., Vichou, I., Vickey, T., Vickey Boeriu, O. E., Viehhauser, G. H. A., Viel, S., Vigani, L., Villa, M., Villaplana Perez, M., Vilucchi, E., Vincter, M. G., Vinogradov, V. B., Vishwakarma, A., Vittori, C., Vivarelli, I., Vlachos, S., Vogel, M., Vokac, P., Volpi, G., von der Schmitt, H., von Toerne, E., Vorobel, V., Vorobev, K., Vos, M., Voss, R., Vossebeld, J. H., Vranjes, N., Vranjes Milosavljevic, M., Vrba, V., Vreeswijk, M., Vuillermet, R., Vukotic, I., Wagner, P., Wagner, W., Wagner-Kuhr, J., Wahlberg, H., Wahrmund, S., Wakamiya, K., Walder, J., Walker, R., Walkowiak, W., Wallangen, V., Wang, C., Wang, C., Wang, F., Wang, H., Wang, H., Wang, J., Wang, J., Wang, Q., Wang, R.-J., Wang, R., Wang, S. M., Wang, T., Wang, W., Wang, W., Wang, Z., Wanotayaroj, C., Warburton, A., Ward, C. P., Wardrope, D. R., Washbrook, A., Watkins, P. M., Watson, A. T., Watson, M. F., Watts, G., Watts, S., Waugh, B. M., Webb, A. F., Webb, S., Weber, M. S., Weber, S. M., Weber, S. W., Weber, S. A., Webster, J. S., Weidberg, A. R., Weinert, B., Weingarten, J., Weirich, M., Weiser, C., Weits, H., Wells, P. S., Wenaus, T., Wengler, T., Wenig, S., Wermes, N., Werner, M. D., Werner, P., Wessels, M., Weston, T. D., Whalen, K., Whallon, N. L., Wharton, A. M., White, A. S., White, A., White, M. J., White, R., Whiteson, D., Whitmore, B. W., Wickens, F. J., Wiedenmann, W., Wielers, M., Wiglesworth, C., Wiik-Fuchs, L. A. M., Wildauer, A., Wilk, F., Wilkens, H. G., Williams, H. H., Williams, S., Willis, C., Willocq, S., Wilson, J. A., Wingerter-Seez, I., Winkels, E., Winklmeier, F., Winston, O. J., Winter, B. T., Wittgen, M., Wobisch, M., Wolf, A., Wolf, T. M. H., Wolff, R., Wolter, M. W., Wolters, H., Wong, V. W. S., Woods, N. L., Worm, S. D., Wosiek, B. K., Wotschack, J., Wozniak, K. W., Wu, M., Wu, S. L., Wu, X., Wu, Y., Wyatt, T. R., Wynne, B. M., Xella, S., Xi, Z., Xia, L., Xu, D., Xu, L., Xu, T., Xu, W., Yabsley, B., Yacoob, S., Yamaguchi, D., Yamaguchi, Y., Yamamoto, A., Yamamoto, S., Yamanaka, T., Yamane, F., Yamatani, M., Yamazaki, T., Yamazaki, Y., Yan, Z., Yang, H., Yang, H., Yang, Y., Yang, Z., Yao, W-M., Yap, Y. C., Yasu, Y., Yatsenko, E., Yau Wong, K. H., Ye, J., Ye, S., Yeletskikh, I., Yigitbasi, E., Yildirim, E., Yorita, K., Yoshihara, K., Young, C., Young, C. J. S., Yu, J., Yu, J., Yuen, S. P. Y., Yusuff, I., Zabinski, B., Zacharis, G., Zaidan, R., Zaitsev, A. M., Zakharchuk, N., Zalieckas, J., Zaman, A., Zambito, S., Zanzi, D., Zeitnitz, C., Zemaityte, G., Zemla, A., Zeng, J. C., Zeng, Q., Zenin, O., Ženiš, T., Zerwas, D., Zhang, D., Zhang, D., Zhang, F., Zhang, G., Zhang, H., Zhang, J., Zhang, L., Zhang, L., Zhang, M., Zhang, P., Zhang, R., Zhang, R., Zhang, X., Zhang, Y., Zhang, Z., Zhao, X., Zhao, Y., Zhao, Z., Zhemchugov, A., Zhou, B., Zhou, C., Zhou, L., Zhou, M., Zhou, M., Zhou, N., Zhou, Y., Zhu, C. G., Zhu, H., Zhu, J., Zhu, Y., Zhuang, X., Zhukov, K., Zibell, A., Zieminska, D., Zimine, N. I., Zimmermann, C., Zimmermann, S., Zinonos, Z., Zinser, M., Ziolkowski, M., Živković, L., Zobernig, G., Zoccoli, A., Zou, R., zur Nedden, M., and Zwalinski, L.

Published
2023
Full Text
View/download PDF

38. First Detection of sub-PeV Diffuse Gamma Rays from the Galactic Disk: Evidence for Ubiquitous Galactic Cosmic Rays beyond PeV Energies

Author

Amenomori, M., Bao, Y. W., Bi, X. J., Chen, D., Chen, T. L., Chen, W. Y., Chen, Xu, Chen, Y., Cirennima, Cui, S. W., Danzengluobu, Ding, L. K., Fang, J. H., Fang, K., Feng, C. F., Feng, Zhaoyang, Feng, Z. Y., Gao, Qi, Gou, Q. B., Guo, Y. Q., Guo, Y. Y., He, H. H., He, Z. T., Hibino, K., Hotta, N., Hu, Haibing, Hu, H. B., Huang, J., Jia, H. Y., Jiang, L., Jin, H. B., Kasahara, K., Katayose, Y., Kato, C., Kato, S., Kawata, K., Kihara, W., Ko, Y., Kozai, M., Labaciren, Le, G. M., Li, A. F., Li, H. J., Li, W. J., Lin, Y. H., Liu, B., Liu, C., Liu, J. S., Liu, M. Y., Liu, W., Lou, Y. -Q., Lu, H., Meng, X. R., Munakata, K., Nakada, H., Nakamura, Y., Nanjo, H., Nishizawa, M., Ohnishi, M., Ohura, T., Ozawa, S., Qian, X. L., Qu, X. B., Saito, T., Sakata, M., Sako, T. K., Shao, J., Shibata, M., Shiomi, A., Sugimoto, H., Takano, W., Takita, M., Tan, Y. H., Tateyama, N., Torii, S., Tsuchiya, H., Udo, S., Wang, H., Wu, H. R., Xue, L., Yamamoto, Y., Yang, Z., Yokoe, Y., Yuan, A. F., Zhai, L. M., Zhang, H. M., Zhang, J. L., Zhang, X., Zhang, X. Y., Zhang, Y., Zhang, Yi, Zhang, Ying, Zhao, S. P., Zhaxisangzhu, and Zhou, X. X.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

We report, for the first time, the long-awaited detection of diffuse gamma rays with energies between 100 TeV and 1 PeV in the Galactic disk. Particularly, all gamma rays above 398 TeV are observed apart from known TeV gamma-ray sources and compatible with expectations from the hadronic emission scenario in which gamma rays originate from the decay of $\pi^0$'s produced through the interaction of protons with the interstellar medium in the Galaxy. This is strong evidence that cosmic rays are accelerated beyond PeV energies in our Galaxy and spread over the Galactic disk., Comment: Accepted for publication in the Physical Review Letters

Published
2021
Full Text
View/download PDF

39. A Nomogram for Predicting the Risk of CKD Based on Cardiometabolic Risk Factors

Author

Yu P, Kan R, Meng X, Wang Z, Xiang Y, Mao B, and Yu X

Subjects
ckd, cardiometabolic risk factors, nomogram, Medicine (General), R5-920
Abstract

Peng Yu,1– 4 Ranran Kan,1,3 Xiaoyu Meng,1,3 Zhihan Wang,1,3 Yuxi Xiang,1,3 Beibei Mao,1,3 Xuefeng Yu1,3 1Department of Endocrinology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of Endocrinology, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 3Branch of National Clinical Research Center for Metabolic Diseases, Hubei, People’s Republic of China; 4Key Laboratory for Molecular Diagnosis of Hubei Province, Wuhan, People’s Republic of ChinaCorrespondence: Xuefeng Yu, Department of Internal Medicine, Tongji Hospital, Huazhong University of Science and Technology, No. 1095, Jiefang Road, Wuhan, 430030, People’s Republic of China, Tel +8602783663331, Email xfyu188@163.comBackground: In China, the spectrum of causes for CKD has been changing in recent years, and the proportion of CKD caused by cardiometabolic diseases, such as diabetes and hypertension continues to increase. Thus, predicting CKD based on cardiometabolic risk factors can to a large extent help identify those at increased risk and facilitate the prevention of CKD. In this study, we aimed to develop a nomogram for predicting CKD risk based on cardiometabolic risk factors.Methods: We developed a nomogram for predicting CKD risk by using a subcohort population of the 4C study, which was located in central China. The prediction model was designed by using a logistic regression model, and a backwards procedure based on the Akaike information criterion was applied for variable selection. The performance of the model was evaluated by the concordance index (C-index), and Hosmer‒Lemeshow goodness-of-fit test. The bootstrapping method was applied for internal validation.Results: During the 3-years follow-up, 167 cases of CKD developed. By using univariate and multivariate logistic regression models, the following factors were identified as predictors in the nomogram: age, sex, HbA1c, baseline eGFR, low HDL-C levels, high TC levels and SBP. The bootstrap-corrected C-index for the model was 0.84, which indicated good discrimination ability. The Hosmer‒Lemeshow goodness-of-fit tests yielded chi-square of 13.61 (P=0.192), and the calibration curves demonstrated good consistency between the predicted and observed probabilities, which indicated satisfactory calibration ability.Conclusion: We developed a convenient and practicable nomogram for the 3‑year risk of incident CKD among a population in central China, which may help to identify high-risk individuals for CKD and contribute to the prevention of CKD.Keywords: CKD, cardiometabolic risk factors, nomogram

Published
2023

40. Views on Suspected Adverse Drug Events in Older Adults with Chronic Conditions: A Qualitative Study

Author

Wang D, Meng X, Liu L, and Wang A

Subjects
the elderly, adverse drug events, medication safety, qualitative study, Medicine (General), R5-920
Abstract

Daqiu Wang,1 Xin Meng,2 Lei Liu,1 Aiping Wang2 1Liaoning University of Traditional Chinese Medicine, Shenyang, People’s Republic of China; 2The First Affiliated Hospital of China Medical University, Shenyang, People’s Republic of ChinaCorrespondence: Aiping Wang, Department of Public Service, the First Affiliated Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang, Liaoning Province, People’s Republic of China, Tel + (0086)02483282288, Fax + (0086)02483282288, Email jianghaoran88@hotmail.comPurpose: To explore how elderly patients with chronic conditions identify and cope with suspected adverse drug events (ADEs) in northern China with the aim of encouraging the elderly to participate in medication safety monitoring.Patients and Methods: A purposive sampling method was adopted to select 15 elderly patients with chronic conditions from a medical center in northern China for semi-structured-interviews, and the data were collated and analyzed through thematic framework analysis.Results: Five major themes and 12 subthemes were refined, namely (1) lack of knowledge: poor awareness of the medications and ambiguous knowledge of ADEs, (2) barriers to identifying suspected ADEs: unawareness and uncertainty, seeking alternative explanations, and limited access to information, (3) the basis for identifying suspected ADEs: time cues and actively seeking communication (4) coping with suspected ADEs: cope with it themselves, not talking to the health care provider on their own initiative and actively seeking communication, and (5) expectations: desire for more reliable information and hope to be safeguarded for medication safety.Conclusion: Due to the lack of relevant knowledge and limited access to information, the elderly were limited in identifying suspected ADEs, but they were positive towards participating in medication safety monitoring and hoped to obtain reliable medication information and detailed medication assessment by enhancing communication with medical professionals in order to achieve medication safety.Keywords: the elderly, adverse drug events, medication safety, qualitative study

Published
2023

41. Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022

Author

Li C, Hao J, Wang C, Yang J, Zheng Y, Zhang K, Hui W, Meng X, Gao J, Li W, and Tang YD

Subjects
thyroid disease, thyroid carcinoma, nontumorous thyroid disease, china, Therapeutics. Pharmacology, RM1-950
Abstract

Chen Li,1,&ast; Jun Hao,2,&ast; Chuangshi Wang,2 Jie Yang,1 Yitian Zheng,1 Kuo Zhang,3 Wen Hui,4 Xiangbin Meng,1 Jun Gao,1 Wei Li,2 Yi-Da Tang1,5 1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, People’s Republic of China; 2Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 3Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 4Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 5Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Wei Li; Yi-Da Tang, Email liwei@mrbc-nccd.com; tangyida@bjmu.edu.cnObjective: The incidence rate of thyroid diseases increased worldwide. This study aims to overview the changing landscape of drug clinical trials on thyroid disease during 2009– 2022.Methods: The detailed information of thyroid disease drug trials registered on the National Medical Products Administration (NMPA) Registration and Information Disclosure Platform for Drug Clinical Studies was searched and collected. The thyroid drug clinical trials were analyzed by the characteristics, time trends, indications, and geographical distribution.Results: Sixty-five thyroid disease drug clinical trials were launched from 2009 to 2022 in China, which included 21 trials in nontumorous thyroid disease and 44 trials in thyroid carcinoma. The number of registered trials of thyroid diseases including thyroid carcinoma and nontumorous thyroid disease increased steadily from 2009 to 2020. Bioequivalence studies accounted for the largest proportion (32[49.2%]), while phase I and Phase II studies both only accounted for 18.5% (12/65). A significant difference was observed in the trials phase, and randomization between thyroid carcinoma and nontumorous thyroid disease. In terms of clinical indications and drug mechanisms, the number of trials in multi-target tyrosine kinase inhibitors for thyroid carcinoma (n=35) ranked first, followed by thyroid hormone for hypothyroidism (n=7), thyrotropin for thyroid carcinoma (n=6). Sixty-five trials were led by 36 principal investigator (PI) units, and more than 30% of PI-leading units were located in Shanghai (n=7) and Beijing (n=4).Conclusion: During the past 13 years, the development of thyroid diseases drugs trials has achieved certain progress in thyroid carcinoma, especially the molecular targeted therapy, yet the development of drug trials on nontumorous thyroid disease was very slow.Keywords: thyroid disease, thyroid carcinoma, nontumorous thyroid disease, China, drug clinical trial

Published
2023

42. Global Trends of Gastrointestinal Endoscopy Anesthesia/Sedation: A Bibliometric Study (from 2001 to 2022)

Author

Xiong Y, Yan H, Qu L, Wang S, Meng X, Zhu X, Zhang P, Yuan S, and Shi J

Subjects
gastrointestinal endoscopy anesthesia, sedation, bibliometric analysis, citespace, vosviewer, Medicine (General), R5-920
Abstract

Yujun Xiong,1,&ast; Haoqi Yan,2,&ast; Lang Qu,3 Shuqi Wang,4 Xiangda Meng,5 Xingyun Zhu,6 Pan Zhang,1 Su Yuan,2 Jihua Shi1 1Department of Gastroenterology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Anesthesiology, Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences; Peking Union Medical College, Beijing, 100037, People’s Republic of China; 3Department of Anesthesiology, Shanghai General Hospital, Shanghai, People’s Republic of China; 4Department of Otolaryngology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People’s Republic of China; 5Department of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China; 6Department of Endocrinology, Beijing Jishuitan Hospital, Beijing, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Su Yuan, Department of Anesthesiology, Fuwai Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College, Xicheng District, Beijing, People’s Republic of China, Email fuwaiys@126.com Jihua Shi, Department of Gastroenterology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100370, People’s Republic of China, Email shijihua1981@sina.comBackground: Gastrointestinal (GI) endoscopy becomes more and more common now in order to diagnose and treat GI diseases, and anesthesia/sedation plays an important role. We aim to discuss the developmental trends and evaluate the research hotspots using bibliometric methods for GI endoscopy anesthesia/sedation in the past two decades.Methods: The original and review articles published from 2001 to December 2022 related to GI endoscopy anesthesia/sedation were extracted from the Web of Science database. Four different softwares (CiteSpace, VOSviewer, and Bibliometrix, Online Analysis Platform of Literature Metrology (Bibliometric)) were used for this comprehensive analysis.Results: According to our retrieval strategy, we found a total of 3154 related literatures. Original research articles were 2855, and reviews were 299. There has been a substantial increase in the research on GI endoscopy anesthesia/sedation in recent 22 years. These publications have been cited 66,418 times, with a mean of 21.04 citations per publication. The US maintained a leading position in global research, with the largest number of publications (29.94%), and China ranked second (19.92%). Keyword burst and concurrence showed that conscious sedation, colonoscopy and midazolam were the most frequently occurring keywords.Conclusion: Our research found that GI endoscopy anesthesia/sedation was in a period of rapid development and demonstrated the improvement of medical instruments and surgical options that had significantly contributed to the field of GI endoscopy anesthesia/sedation. The US dominates this field, and the selection and dosage of sedative regimens have always been the foci of disease research to improve comfort and safety, while adverse events and risks arouse attention gradually. In the past 20 years, hotspots mainly focus on upper gastrointestinal endoscopy, gastroscopy, and esophagogastroduodenoscopy. These data would provide future directions for clinicians and researchers regarding GI endoscopy anesthesia/sedation.Keywords: gastrointestinal endoscopy anesthesia, sedation, bibliometric analysis, CiteSpace, VOSviewer

Published
2023

43. Impact of Serum Cystatin C Level on Long-Term Cognitive Impairment After Acute Ischemic Stroke and Transient Ischemic Attack

Author

Zuo L, Dong Y, Pan Y, Yan H, Meng X, Li H, Zhao X, Wang Y, and Liao X

Subjects
mild stroke, post stroke cognitive impairment, cystatin c, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Lijun Zuo,1 Yanhong Dong,2 Yuesong Pan,3 Hongyi Yan,3 Xia Meng,3 Hao Li,3 Xingquan Zhao,1 Yilong Wang,1 Yongjun Wang,1 Xiaoling Liao1 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Clinical Research Centre, Singapore, 117597, Singapore; 3National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Xiaoling Liao, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119, South Fourth Ring West Road, Fengtai District, Beijing, 100070, People’s Republic of China, Tel +86-010-59978350, Fax +86-010-59973383, Email liao828@sina.comObjective: Cognitive impairment after stroke/transient ischemic attack (TIA) has a high prevalence. Cystatin C (CysC) has been found as a novel biomarker of neurodegenerative diseases, such as dementia and Alzheimer’s disease. We aimed to explore the possible correlations of serum CysC level with cognitive impairment in patients who had mild ischemic stroke and TIA after 1 year.Methods: We measured serum CysC level in 1025 participants with a minor ischemic stroke/TIA from enrolled from the Impairment of Cognition and Sleep (ICONS) study of the China National Stroke Registry-3 (CNSR-3). They were divided into four groups according to quartiles of baseline CysC levels. Patients’ cognitive functions were assessed by Montreal Cognitive Assessment (MoCA)-Beijing at day 14 and at 1 year. Multiple logistic regression models were performed to evaluate the relationship between CysC and post-stroke cognitive impairment (PSCI) at 1-year follow-up.Results: Cognitive impairment was defined as MoCA-Beijing ≤ 22. Most patients were in 60s (61.52± 10.97 years old) with a median (interquartile range) National Institute of Health Stroke Scale(NIHSS) score of 3.00 (4.00) and greater than primary school level of education, and 743 participants (72.49%) were male. Among the 1025 participants, 331 participants (32.29%) patients suffered PSCI at 1-year follow-up. A U-shaped association was observed between CysC and 1-year PSCI [quartile (Q)1 vs Q3: adjusted odds ratio (aOR) 2.69, 95% CI 1.67– 4.34, p < 0.0001; Q2 vs Q3: aOR 1.63, 95% CI 1.03– 2.57, p = 0.0354; Q4 vs Q3: aOR 1.83, 95% CI 1.16– 2.87, p = 0.009]. Moreover, the U-shaped trends were also found between CysC level and the subscores of attention, recall, abstraction and language in MoCA.Conclusion: CysC showed a U-shaped correlation with 1-year overall cognitive function. It is probable that measurement of the serum CysC level would aid in the early diagnosis of PSCI.Keywords: mild stroke, post stroke cognitive impairment, cystatin C

Published
2023

46. Rapid generation of metastable helium Bose-Einstein condensates

Author

Abbas, A. H., Meng, X., Patil, R. S., Ross, J. A., Truscott, A. G., and Hodgman, S. S.

Subjects
Condensed Matter - Quantum Gases
Abstract

We report the realisation of Bose-Einstein condensation (BEC) of metastable helium atoms using an in-vacuum coil magnetic trap and a crossed beam optical dipole trap. A novel quadrupole-Ioffe configuration (QUIC) magnetic trap made from in-vacuum hollow copper tubes provides fast switching times while generating traps with a 10G bias, without compromising optical access. The bias enables in-trap 1D doppler cooling to be used, which is the only cooling stage between the magneto-optic trap (MOT) and the optical dipole trap. This allows direct transfer to the dipole trap without the need for any additional evaporative cooling in the magnetic trap. The entire experimental sequence takes 3.3 seconds, with essentially pure BECs observed with $\sim 10^6$ atoms after evaporative cooling in the dipole trap., Comment: 6 pages, 4 figures

Published
2021
Full Text
View/download PDF

47. Nonstochastic Bandits with Infinitely Many Experts

Author

Meng, X. Flora, Sarkar, Tuhin, and Dahleh, Munther A.

Subjects
Computer Science - Machine Learning, Statistics - Machine Learning
Abstract

We study the problem of nonstochastic bandits with expert advice, extending the setting from finitely many experts to any countably infinite set: A learner aims to maximize the total reward by taking actions sequentially based on bandit feedback while benchmarking against a set of experts. We propose a variant of Exp4.P that, for finitely many experts, enables inference of correct expert rankings while preserving the order of the regret upper bound. We then incorporate the variant into a meta-algorithm that works on infinitely many experts. We prove a high-probability upper bound of $\tilde{\mathcal{O}} \big( i^*K + \sqrt{KT} \big)$ on the regret, up to polylog factors, where $i^*$ is the unknown position of the best expert, $K$ is the number of actions, and $T$ is the time horizon. We also provide an example of structured experts and discuss how to expedite learning in such case. Our meta-learning algorithm achieves optimal regret up to polylog factors when $i^* = \tilde{\mathcal{O}} \big( \sqrt{T/K} \big)$. If a prior distribution is assumed to exist for $i^*$, the probability of optimality increases with $T$, the rate of which can be fast., Comment: Added numerical experiments

Published
2021

48. A $\Delta R\sim 9.5$ mag Super Flare of An Ultracool Star Detected by $\text{SVOM/GWAC}$ System

Author

Xin, L. P., Li, H. L., Wang, J., Han, X. H., Xu, Y., Meng, X. M., Cai, H. B., Huang, L., Lu, X. M., Qiu, Y. L., Wang, X. G., Liang, E. W., Dai, Z. G., Wang, X. Y., Wu, C., Zhang, J. B., Li, G. W., Turpin, D., Feng, Q. C., Deng, J. S., Sun, S. S., Zheng, T. C., Yang, Y. G., and Wei, J. Y.

Subjects
Astrophysics - Solar and Stellar Astrophysics
Abstract

In this paper, we report the detection and follow-ups of a super stellar flare GWAC\,181229A with an amplitude of $\Delta R\sim$9.5 mag on a M9 type star by $\text{SVOM/GWAC}$ and the dedicated follow-up telescopes. The estimated bolometric energy $E_{bol}$ is $(5.56-9.25)\times10^{34}$ ergs, which places the event to be one of the most powerful flares on ultracool stars. The magnetic strength is inferred to be (3.6-4.7) kG. Thanks to the sampling with a cadence of 15 seconds, a new component near the peak time with a very steep decay is detected in the $R$-band light curve, followed by the two-component flare template given by Davenport et al. (2014). An effective temperature of $5340\pm40$ K is measured by a blackbody shape fitting to the spectrum at the shallower phase during the flare. The filling factors of the flare are estimated to be $\sim$30\% and 19\% at the peak time and at 54 min after the first detection. The detection of the particular event with large amplitude, huge-emitted energy and a new component demonstrates that a high cadence sky monitoring cooperating with fast follow-up observations is very essential for understanding the violent magnetic activity., Comment: 14 pages, 12 figures, 4 tables, accepted by ApJ

Published
2020
Full Text
View/download PDF

50. Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients

Author

Gan Y, Meng X, Lei N, Yu H, Zeng Q, and Huang Q

Subjects
meropenem, critically ill patients, pharmacokinetics, therapeutic drug monitoring, Infectious and parasitic diseases, RC109-216
Abstract

Yuhong Gan,1 Xiaobin Meng,1 Nanfeng Lei,1 Hong Yu,1 Qingkao Zeng,2 Qingyan Huang3,4 1Department of Clinical Pharmacy, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Department of Intensive Care Unit, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 3Center for Precision Medicine, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 4Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of ChinaCorrespondence: Qingyan Huang, Center for Precision Medicine, Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, No. 63 Huangtang Road, Meijiang District, Meizhou, 514031, People’s Republic of China, Tel +86 753 2131 591, Email Huangqingyan03@163.comPurpose: This study aimed to investigate the pharmacokinetics and target attainment of meropenem and compare the effect of meropenem dosing regimens in critically ill patients.Patients and Methods: Thirty-seven critically ill patients who were administered meropenem in intensive care units were analyzed. Patients were classified according to their renal function. Pharmacokinetic parameters were assessed based on Bayesian estimation. The target attainment of 40%fT > MIC (fraction time that the free concentration exceeds the minimum inhibitory concentration) and 100%fT > MIC with the pathogen MIC of 2 mg/L and 8 mg/L were specially focused. Furthermore, the effects of standard dosing (1g meropenem, 30 min intravenous infusion every 8h) and non-standard dosing (dosage regimens except standard dosing) were compared.Results: The results showed that the values of meropenem clearance (CL), central volume of distribution (V1), intercompartmental clearance (Q), and peripheral volume of distribution (V2) were 3.3 L/h, 9.2 L, 20.1 L/h and 12.8 L, respectively. The CL of the patients among renal function groups was significantly different (p < 0.001). The tow targets attainment for the pathogen MIC of 2 mg/L and 8 mg/L were 89%, 73%, 49% and 27%, respectively. The severe renal impairment group has higher fraction of target attainment than the other group. The standard dosing achieved the target of 40%fT > 2/8 mg/L (85.7% and 81%, respectively) and patients with severe renal impairment achieved the target fraction of 100% for 40%fT > MIC. Additionally, there was no significant difference between standard and non-standard dosing group in target attainment.Conclusion: Our findings indicate that renal function is an important covariate for both meropenem pharmacokinetics parameters and target attainment. The target attainment between standard and non-standard dosing group was not comparable. Therefore, therapeutic drug monitoring is indispensable in the dosing adjustment for critically ill patients if it is available.Keywords: meropenem, critically ill patients, pharmacokinetics, therapeutic drug monitoring

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results